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Medulloblastoma, the most common malignant pediatric brain tumor, is currently treated with nonspecific 
cytotoxic therapies including surgery, radiation, and aggressive chemotherapy. Despite enhancements in 
treatment strategies, the majority of medulloblastoma cancer patients are left with significant neurological, 
intellectual and physical disabilities secondary to the effects of these nonspecific cytotoxic therapies on the 
developing brain. Therefore, additional therapeutic possibilities need to be explored to minimize adverse effects 
and increase response rate in medulloblastoma patients. 
A major challenge of brain tumor surgery is removing all of the tumor tissues while preserving as much 
healthy brain tissue as possible. The extent of surgical resection can modulate 5-year survival potential by 30-
50%, far greater than the impact of any drug - yet there has never been a clinical trial focused on improving 
surgical outcomes. With the goal of improving detection of cancer foci during surgical resection, our lab 
developed NP-chitosan-Chlorotoxin-Cy5.5 nanoparticle, also known as tumor paint nanoparticle. In the first part 
of my thesis, I have shown simple near-infrared fluorescence based methodology to assess the pharmacokinetic 
properties of these nanoparticles. These data obtained can be incorporated into early nanoparticle synthesis 
decisions as well as more detailed documentation required for the FDA approval for human clinical trials. 
As medulloblastoma exhibits marked intertumor heterogeneity, with at least four distinct molecular 
variants, patients may require separate therapeutic strategies. The development of a targeted inhibitor of a 
pathway that is implicated in malignancy, together with identification of patient populations most likely to 
respond to these therapies may offer more effective therapeutic option than standard treatment strategies available 
in clinics. The second part of my dissertation work involves investigating the efficacy and pharmacodynamic 
effects ofsaridegib (IPI-926), one of the Sonic hedgehog (Shh) pathway inhibitors identified, in Shh-driven 
mouse model of medulloblastoma. Although saridegib has shown effectiveness in reducing and eliminating 
tumor cells in mice initially, drug resistance inevitably occurred. Understanding the mechanisms of resistance to 
targeted therapy and developing strategies to overcome them are critical for achieving long-term efficacy of 
targeted therapy in patients. Therefore, I further investigated mechanisms adopted by medulloblastoma cells 
during cancer progression. I found that overexpression of the Pgp drug transporter contributes to drug resistance 
in Shh-driven medulloblastoma and the combination of saridegib with Pgp inhibitor partially reversed the drug 
resistance. Our data provide a strong rationale for the use of a concurrent combination of Shh pathway inhibitors 
with Pgp inhibitors for the treatment of medulloblastoma and suggest that this approach may delay the 
development of resistance to Shh pathway inhibitors. 
The last part of my dissertation work involved engineering cysteine rich peptides toward the goal of 
producing Pgp-insensitive therapies for medulloblastoma. Toward this goal, I used a nature-derived knottin 
peptide as a scaffold and computationally designed variants that could specifically bind to glypican-2, which is 
overexpressed in medulloblastoma. My aim was to express only a fragment of midkine, a known ligand of 
glypican-2, that would bind to glypican-2 but not crosslink with growth factor signaling pathways, thereby 
inhibiting tumor growth. Our ultimate goal is to generate cysteine knot peptide variants capable of targeting and 
killing brain tumor initiating cells in medulloblastoma patients. This work may provide significant clinical 
benefit to human medulloblastoma patients, and may serve as an important step towards integrating knottin drugs 
into mainstream therapy. 
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CHAPTERl 
Introduction 
The Cerebellum 
The cerebellum is located at the base of the brain and occupies approximately 10% of total brain 
volume and contains more than half ofthe total number of neurons in the human brain (Andersen et aI., 
1992). In addition to its classic functions in motor coordination and balance, there is increasing evidence 
that the cerebellum is also involved in higher cognitive processes such as emotion and cognition (Hatten 
and Roussel, 2011; Schutter and van Honk, 2005). 
The cerebellar cortex has a remarkably simple laminar structure. It consists of an outer cortical 
structure and set of subcortical nuclei, the cerebellar nuclei, which project to cerebellar targets (Figure 
1.1 A). Previous studies indicate that the dorsomedial ventricular zone gives rise to the major output 
neurons of the cerebellar cortex, the Purkinje cells, neurons of the cerebellar nuclei, and cerebellar 
interneurons. A secondary germinal zone forms along the rostral rhombic lip, which generates the 
cerebellar granule neurons (GNPs) (Figure 1.1 B) (Laine and Axelrad, 2002). These GNPs undergo 
proliferation at embryonic day (E) 10.5 in mouse, then between E12-E15 they migrate dorsally over to the 
roof of the cerebellar anlage to form the external granular layer (EGL) (Fairweather et aI., 2008; Olive et 
aI., 2009). In the postnatal (P) phase, the GNPs undergo massive proliferation in response to mitogens 
secreted by Purkinje cells. This proliferation phase peaks at P5-P8 and declines thereafter to stop at 
around PIS. From about P8 on, GNPs in the EGL then exit the cell cycle and initiate their inward radial 
migration. They move past the growing network ofPurkinje cells in the molecular layer (ML). Once 
passed the ML, GNPs further differentiate to become mature granule neurons and form the internal 
granular layer (IGL) (Lerner et aI., 2011). Neuronal differentiation is completed in the IGL by around 
P21 in mice and a year after birth in humans (Wang and Zoghbi, 2001). The final development of the 
cerebellum requires a fine balance between proliferation, migration, differentiation, and cell death. 
Sonic hedgehog pathway 
The primary cilium is a microtubule based membrane structure that projects from the surface of 
many eukaryotic cells (Neunaber et aI., 2010). The primary cilium receives mechanical and chemical 
signals from other cells and the surrounding environment, and transmits these signals to the nucleus to 
elicit a cellular response. Recent work has shown that primary cilia concentrate receptors and signaling 
transduction components that are important in development including the Sonic Hedgehog (Shh) 
signaling (Michaud and Yoder, 2006). 
The Shh pathway is an essential embryonic signaling pathway that regulates body patterning and 
organ development. In adults, Shh signaling is normally dormant, but its inappropriate activation has 
been linked to several human cancers (Ng and Curran, 2011). Two important molecules in Shh signaling 
are Patched! (Ptchl) and Smoothened (Smo), which are transmembrane proteins involved in Shh-
dependent trafficking in the primary cilia. In the absence of Shh, Ptchl represses the activity of Smo 
presumably by preventing its translocation into primary cilium from intracellular endosomes (Yolk and 
Loscher, 2005). Without activation of Smo, SUFU (Suppressor of fused; important negative regulator of 
Shh signaling) inactivates the glioma-associated oncogene family zinc finger (Gli) transcription factors, 
converting full-length Gli proteins into truncated repressor form: Gli-R. Full-length Gli proteins are 
sequentially phosphorylated by GSK3, protein kinase A, and casein kinase I to form Gli-R, leading to 
partial degradation (Tempe et aI., 2006; Wang and Li, 2006). Gli-R then translocates to the nucleus to 
repress Shh target genes (Osterlund and Kogerman, 2006; Yolk and Loscher, 2005). Binding of Shh to its 
receptor Ptchl leads to internalization of Ptch 1. The inhibition of Smo is then relieved, allowing 
accumulation of Smo in the primary cilia where dissociation of SUFU-Gli complex is promoted. This 
results in nuclear translocation and activation of G li 1 and Gli2 transcription factors, and degradation of 
the repressor form, Gli-R (Osterlund and Kogerman, 2006; Yolk and Loscher, 2005). Gli proteins 
stimulate the transcription of Shh pathway target genes such as Ptch, Wnt, bone morphogenetic protein 
(BMP), etc (Figure 1.2). 
Detection of loss of function mutations in the Shh signaling pathway in familial basal cell 
carcinoma (Gorlin syndrome) patients established a clear genetic contribution of Shh pathway activity to 
oncogenesis (Johnson et aI., 1996). Since these initial findings, additional evidence was provided by the 
identification of somatic mutations that cause activation of Shh signaling in various types of human 
cancers, including basal cell carcinomas (BCCs), medulloblastoma, rhabdomyosarcoma, leukemia, 
gastrointestinal, lung, ovarian, pancreatic, breast and prostate cancers (Yang et aI., 2010). More definitive 
proof that aberrant Shh signaling can induce cancers has come from transgenic mouse studies in which 
conditional loss of function ofPtchl or gain offunction of Smo recapitulate BCC and medulloblastoma 
(Pasca di Magliano and Hebrok, 2003). 
Sonic hedgehog pathway during Cerebellar Development 
The characterization of Shh-activated mutant mice has contributed to our understanding of Shh 
signaling and its role in cerebellar development. In the cerebellum, the expansion of GNPs is orchestrated 
principally by Shh. Shh is secreted by the Purkinje cells around E 1 7 and drives the proliferation of GNPs 
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in the postnatal phase of cerebellar development in the EGL. Shh regulates both size and foliation of the 
cerebellum (Corrales et aI., 2006), and the duration and intensity of the proliferation phase of EGL is 
critical for the final morphology and function of the cerebellum. Persistent Shh signaling results in 
uncontrolled proliferation of GNPs and can cause medulloblastoma, a cerebellar pediatric cancer. 
Medulloblastoma 
Medulloblastoma is the most common malignant pediatric brain tumor (Becker et aI., 2005). It is 
thought to arise from genetic anomalies in developmental pathways required for normal maturation of the 
cerebellum. The median age at diagnosis is 5 years with the range extending into young adulthood. 
Standard treatment strategies for medulloblastoma involve nonspecific cytotoxic therapies including 
surgical resection, whole-brain and spinal cord radiation, and aggressive chemotherapy. The overall 
survival rate for patients with medulloblastoma has reached 70-80% under standard treatment protocols 
(Siegel et aI., 2012; Rutkowski et aI., 2010). Although the survival rates have improved over the years, 
the majority of survivors suffer from significant neurological, intellectual and physical disabilities 
secondary to the effects of nonspecific cytotoxic therapies on the developing brain (Becker et a!., 2004). 
Gene expression profiling of primary medulloblasotmas have led to identification of mUltiple 
molecularly distinct subgroups (Amaral et a!., 2004; Cho et aI., 2011; Ramalho et aI., 2004). Genetic and 
molecular genetic analyses of medulloblastoma have identified changes in the regulation of signaling 
pathways that are important for cerebellar progenitor cell neurogenesis, including pathways that promote 
growth. Four principle subgroups of medulloblastoma include WNT, SHH, Group 3 and Group 4. (Since 
less is known about the biology of the Group 3 and Group 4, the generic names are used until the 
underlying biology driving these subgroups is better characterized). Medulloblastoma subgroups have 
highly disparate cytogenetics, mutational spectra and gene expression signatures, in addition to divergent 
clinical phenotypes such as patient demographics, tumor cell histology and patient outcome. For 
instance, studies of genetically engineered mice show that medulloblastoma tumors arise from at least two 
different progenitor populations. SHH subgroup medulloblastomas are generated from cerebellar GNPs 
(Metcalfe and de Sauvage, 2011) whereas WNT subgroup tumors develop from lower rhombic lip 
progenitors (Tremblay et aI., 2009). There is also marked clinical difference between WNT and SHH 
subgroup medulloblastomas. WNT medulloblastomas have the best prognosis of any subgroup (greater 
than 95% survival) and are the least common of the four subgroups (Ellison et a!., 2011). These tumors 
typically occur in older children, and exhibit class histology. WNT subgroup ubiquitously harbors 
somatic mutations of CTNNB 1 that promote stabilization and nuclear localization of ~-catenin (Zurawel 
et aI., 1998). Meanwhile, SHH medulloblastomas represent intermediate prognosis subgroup with overall 
survival ranging from 60% to 80% (Taylor et al., 2012). SHH subgroup is predominant in infants and 
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young adults, and desmoplastic histology is almost exclusively restricted to this group. Around half of 
SHH activated medulloblastoma tumors have confirmed loss of PTCH1 , loss of SUFU, or gain-of-
function SMO mutations (Brugieres et aI., 2010; Yauch et aI., 2009). 
The establishment of the subgrouping of medulloblastoma has revamped how medulloblastoma 
needs to be viewed and approached in the design of future clinical trials. As each subgroup has very 
distinct molecular genetic profiles, each requires subgroup specific therapeutic approach. Although the 
initial studies with Shh inhibitors have shown early promise, targeted therapies based on genetics and 
molecular characteristics have not been routinely implemented in the clinic. It is expected that in the 
future, medulloblastoma patients will be stratified and treated based on their biological markup of their 
disease, which will hopefully lead to improved patient outcomes with less adverse effects. My 
dissertation was aimed at furthering our understanding of Shh pathway targeted therapy and hence I focus 
on the Shh pathway inhibitors in the section below. 
Small-molecule Shh pathway inhibitors for cancer therapy 
Our understating of Shh signaling pathway signaling has led to the discovery of small molecule 
inhibitors of the Shh pathway. The discovery of these Shh pathway modulators provides an avenue to 
regulate the activity of Shh pathway implicated in medulloblastoma, advanced basal cell carcinoma 
(BCC), pancreatic cancer, prostate cancer and developmental disorders. The first generations of Shh 
inhibitors are cyclopamine and jervine, which were isolated from corn lilies as compounds causing 
teratogenic effects in lambs (Bryden et aI., 1971; Winkler et aI., 2009). Cyclopamine interfere with Shh 
signaling by binding directly to Smo protein (Chen et aI., 2002) and was shown to inhibit proliferation 
and to induce apoptosis in various types of cancers. Despite the attractive pharmacological effects against 
a number of cancer xenografts, the clinical development of cyclopamine as a therapeutic agent in cancer 
was hampered by its poor pharmacokinetic properties (e.g., weak potency, rapid clearance, chemical 
instability). This encouraged a search for novel inhibitors with preferential characteristics for drug 
development. Therefore, several synthetic and semi-synthetic small molecule inhibitors of Shh signaling 
pathway have been discovered. Currently, all the Shh pathway therapeutics in clinical trials act at the 
level of Smo and thus would not be effective against tumors that harbor molecular lesions downstream of 
Smo (See Table 1.1 for summary of Smo inhibitors in clinical trials). 
GDC-0449 (vismodegib) produced by Genentech is a more potent and specific synthetic oral Smo 
inhibitor that showed activity in inhibiting the tumor growth. GDC-0449 was recently approved by the 
Food and Drug Administration (FDA) for treatment of advanced BCC (January 2012). Clinical trials are 
ongoing in various cancers including small cell lung cancer, pancreatic, esophageal, gastric, breast and 
prostate cancers. In a case report of a medulloblastoma patient, treatment with GDC-0449 initially 
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resulted in rapid regression of the tumor and reduction of symptoms; however, the tumor ultimately 
relapsed with D473H resistance mutation in Smo (Yauch et al., 2009). 
LDE225 produced by Novartis is another small molecule inhibitor that specifically inhibits Smo 
in the Shh signaling pathway. LDE225 is currently being investigated in Phase I or II trials in patients 
with BCC and other advanced solid tumors. The results demonstrated that LDE225 was well tolerated 
and LDE225-treated BCCs displayed complete clinical response in three cases, partial response in nine 
cases, and no response in one case (Skvara et al., 2011). In Patched mutant medulloblastoma mice, 
LDE225 has been shown to inhibit Shh signaling and induced tumor regression. However, as for GDC-
0449, drug resistance was observed during the course ofLDE225 treatment. The mechanisms of 
resistance include amplification of Gli2, point mutations in Smo, and upregulation of signaling pathways 
that interact with Shh, such as PI3K. Interestingly, the combination treatment ofLDE225 with PI3K 
inhibitor or dual PI3K-mammalian target ofrapamycin (mTOR) inhibitor markedly delayed the 
development of resistance, suggesting the importance of multiple signaling inhibitions for cancer therapy 
(Buonamici et al., 2010). 
Saridegib (lPI-926) produced by Infinity is a semi-synthetic cyclopamine analog that inhibits 
Smo in the Shh pathway. Several Phase I and II clinical trials using saridegib were conducted in different 
types of cancers including pancreatic cancer, and chondrosarcoma. Despite the promising preclinical 
studies, the saridegib clinical trial was stopped in all trials when interim analysis revealed that metastatic 
pancreatic cancer patients treated with gemcitabine plus placebo showed longer survival than patients on 
reduced dose of gemcitabine plus saridegib. 
Trials with Shh pathway inhibitors showed beneficial effects on various cancers. Shh directed 
therapeutics could provide promising strategies for treating Shh-activated cancers. It is better to use a 
specific small molecule inhibitor in order to minimize adverse effects; however, targeting one molecule 
may not be sufficient enough to kill cancer cells and reverse malignant status because cancer is a disease 
of multiple signals and signal networks, which contributes to treatment failure. Therefore, multi-targeting 
approach (targeting Shh signaling combined with inhibitors of other key pathways such as Akt, Wnt, 
Notch, TGF-~) could become a novel strategy for designing personalized therapy to win the battle against 
cancer. 
Aims of my Dissertation Research 
The objective of my dissertation research was to understand the molecular mechanisms 
underlying tumorigenesis and drug resistance in medulloblastoma with the goal of developing more 
efficacious targeted therapies. The three areas I have been interested in are 1) developing a molecular 
imaging agent for the localization of the malignant tumor during surgical resection, 2) understanding drug 
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resi~tance mechanisms against Shh pathway targeted therapy and strategies to overcome drug resistance, 
and 3) developing tumor specific peptide variants that binds to receptors present on tumor cells. Toward 
this goal, first, I aimed to characterize pharmacokinetic properties of dual modality (MRI and NIR 
fluorescence imaging) tumor targeting agent for the diagnosis, monitoring, and surgical guidance of 
cancer. The findings from this study are described in Chapter 2. Toward my second aim, a vast array of 
resistance mechanisms, involving mutations or amplification of the target protein, overexpression of 
downstream signaling pathways, possibility of crosstalk with other signaling pathways, and 
overexpression of drug transporters, were examined. My finding that altered expression and activity ofP-
glycoprotein (Pgp) drug transporter plays a critical role in drug resistance in Shh-driven mouse model of 
medulloblastoma is described in Chapter 3. Finally, I aimed to develop and computationally design 
knottin peptides that target specific proteins and pathways that are overly expressed in medulloblastoma 
tumors. These peptides would eventually be used to target chemotherapy specifically to medulloblastoma 
cells . My findings are summarized in Chapter 4. 
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Figure 1.1 Cerebellum architecture and development 
(A) Arrangement of Purkinje cells and granule cells in a layered cerebellum follows a stereotyped 
arrangement. A subpial molecular layer is composed of Purkinje cell dendritic trees and granule cell 
axons and few cell bodies. A monolayer of Purkinje cell bodies separates the molecular layer from hugely 
populous internal granule layer. (B) This arrangement develops via two phases of proliferation and 
migration. At the rhombic lip, GNPs migrate tangentially into a superficial, transient external granule 
layer. Here, they proliferate in a series of symmetrical divisions in response to Shh signaling from 
underlying Purkinje cells. The vastly expanded post-mitotic derivatives of the EGL then migrate through 
the Purkinje cell layer. (Figure modified from Butts and et aI., 2010) 
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Figure 1.2 Mechanics of the vertebrate Shh signaling 
nucleus 
(A) In the absence of Shh, its receptor Patchedl (PTCHl), located on the plasma membrane inhibits 
Smoothened (SMO) by possibly exporting an endogenous agonist of SMO outside the cell. Under this 
circumstance, different kinases phosphorylate Gli2/3, creating a repressor form of this transcription factor 
(Glt). Iguana and SUFU prevent the active form of Gli (GliA) from transactivating Shh-responsive genes. 
(B) Upon binding of Shh, Ptchl is internalized relieving the inhibition on SMO. Intracellular 
accumulation ofPTCHl activates SMO, which itselftranslocate to the plasma membrane in primary 
cilium. SMO then engages yet unknown components of the signaling pathway, culminating in activation 
of the Gli proteins, which regulate the expression of Shh target genes. (Figure taken from Rubin and de 
Perrot, 2012) 
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Agent Target Manufacturer Phase Number IC50 ~M Response Reference 
of trials (Potency 
compared to 
cyclopamine) 
GDC-0449 Smo Genentech Phase II 28 ~0.003 BCC (18/33) (Doggrell, 2010) 
(~170X) Metastatic BCC (9/18) (Amin et aI., 2010) 
Advanced BCC (3/3) (LoRusso et aI., 2011) 
Medulloblastoma (1 /1) 
LDE225 Smo Novartis Phase I, II 5 N.D NBCCS with BCC (Skvara et aI., 2011) 
(12113) 
Medulloblastoma (no 
result) 
PF-04449913 Smo Pfizer Phase I 2 N.D 
Saridegib Smo Infinity Phase I, II 2 0.015 (~30X) BCC (4117) 
(IPI-926) 
BMS-833923 Smo Bristol-Myers Phase I, II 5 N.D 
Squibb 
Table 1.1 Shh pathway inhibitors in current clinical trials 
Abbreviations: N.D, not detennined 
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CHAPTER 2 
Rapid Pharmacokinetic and Biodistribution Studies Using Chlorotoxin-Conjugated Iron Oxide 
Nanoparticles: A Novel Non-Radioactive Method 
Modified from an article published in Plos One: 
Lee MJ-E, Veiseh 0, Bhattarai N, Sun C, Hansen SJ, et al. Rapid Pharmacokinetic and Biodistribution 
Studies Using Chlorotoxin-Conjugated Iron Oxide Nanoparticles: A Novel Non-Radioactive Method. 
(2010) PLoS ONE 5(3): e9536. doi:l0.13711joumal.pone.0009536 
Summary 
Recent advances in nanotechnology have led to the development of biocompatible nanoparticles 
for in vivo molecular imaging and targeted therapy. Many nanoparticles have undesirable tissue 
distribution or unacceptably low serum half-lives. Pharmacokinetic (PK) and biodistribution studies can 
help inform decisions determining particle size, coatings, or other features early in nanoparticle 
development. Unfortunately, these studies are rarely done in a timely fashion because many 
nanotechnology labs lack the resources and expertise to synthesize radioactive nanoparticles and evaluate 
them in mice. 
To address this problem, we developed an economical, radioactivit~-free method for assessing 
serum half-life and tissue distribution ofnanoparticles in mice. Iron oxide nanoparticles coated with 
chitosan and polyethylene glycol that utilize chlorotoxin as a targeting molecule have a serum half-life of 
7-8 hours and the particles remain stable for extended periods of time in physiologic fluids and in vivo. 
Nanoparticles preferentially distribute to spleen and liver, presumably due to reticuloendothelial uptake. 
Other organs have very low levels of nanoparticles, which is ideal for imaging most cancers in the future. 
No acute toxicity was attributed to the nanoparticIes. 
We report here a simple near-infrared fluorescence based methodology to assess PK properties of 
nanoparticIes in order to integrate pharmacokinetic data into early nanoparticle design and synthesis. The 
nanoparticIes tested demonstrate properties that are excellent for future clinical imaging strategies and 
potentially suitable for targeted therapy. 
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Introduction 
Nanomedicine, the application of nanotechnology in the practice of medicine, offers many 
advantages over conventional therapeutics. Properly developed, nanoparticles and other nanoscale 
therapeutics offer improved intracellular penetration, enhanced absorption into selected tissues, better 
pharmacokinetic (PK) properties, increased clinical efficacy and reduced toxicity (Peer et al., 2007). 
Nanomedicine faces several challenges during preclinical development. Recently, the Food and Drug 
Administration (FDA) and the Alliance for NanoHealth (ANH) recognized seven scientific challenges in 
bringing nanomedicine to patients (Peer et al., 2007). Among the seven challenges, three emphasize the 
importance of studying the pharmacokinetics of nanotechnology-based therapeutics. These include 
evaluation ofnanoparticle biodistribution following systemic injection, the study of transport across 
biological barriers, and the development of imaging modalities for tracking the fate of nanomedicine over 
time. 
Pharmacokinetic and biodistribution characteristics are important parameters to consider when 
designing and testing novel nanoparticles. In order to achieve an effective level of nanoparticles in the 
target tissue or tumor site, targeted nanoparticles should transition from circulating blood to the tissue of 
interest and bind to its molecular target as a first step in nanoparticle retention or cellular internalization. 
Unfortunately, many types of systemically injected nanoparticles are rapidly cleared from the blood 
stream by the reticuloendothelial system (RES) and the mononuclear phagocytic system (MPS) mainly 
through the liver, spleen, and bone marrow (Peer et al., 2007; Ferrari, 2005) resulting in a low therapeutic 
index. Development ofnanoparticles that avoid rapid clearance is a necessary requirement for sufficient 
delivery to the desired target (Ferrari, 2005; Alexis et al., 2008). Nanoparticles with an extremely high 
circulation half-life should also be avoided as this may contribute to off target tissue toxicity and reduced 
signal-to-noise ratio due to non-specific binding. 
Nanoparticle core, linker, and coating materials along with synthesis and purification techniques 
influence serum half-life and biodistribution (Emerich and Thanos, 2006). Linker molecules like chitosan 
can sterically stabilize the corona, and prevent aggregation. Surface modification of nanoparticles with 
synthetic polymers like polyethylene glycol (PEG), polyvinyl alcohol (PVA), or polysaccharide can 
enhance solubility of hydrophobic materials, minimize nonspecific binding, prolong circulation time, and 
enhance tumor specific targeting (Laurent et al., 2008; Sheng et al., 2009). Since chemical and physical 
properties of nanoparticles determine their in vivo fate, it is desirable to measure pharmacokinetic profiles 
early in the development process so that this information can be used to influence nanoparticle design and 
candidate prototype selection. Traditionally, pharmacokinetic studies were based on either quantification 
of the therapeutic agent (e.g., using HPLC and mass spectroscopy) or by radiolabeling the agent and 
measuring radioactivity in homogenized tissue (Rossin et al., 2005; Kaul and Amiji, 2004). Both 
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approaches are relatively expensive, time consuming, and outside of the expertise of many nanoparticie 
synthesis laboratories. Even though pharmacokinetic data is critical in making decisions regarding 
particle size, coating, synthesis procedures, and purification methods these studies are often conducted in 
the late stages ofnanoparticie development due to these roadblocks. Here we describe a new, fast, and 
economical method for evaluating PK and biodistribution properties ofnanoparticies using near infrared 
(NIR) based technology that allows these critical steps to be performed early in the nanoparticie 
development. 
Some groups, inciuding ours, incorporate near infrared fluorophore (NIRF) molecules into 
nanoparticie synthesis to facilitate intra-operative visualization of targeted cells or tissues (Josephson et 
aI., 2002; Kircher et aI., 2003). We capitalized on this reporter molecule to assess serum half-life and 
biodistribution of a chitosan-conjugated iron oxide core nanoparticie. This nanoparticle serves as a 
platform to deliver targeted anticancer therapeutics and as an imaging agent for visualizing tumors in 
mice (Veiseh et aI., 2009). The results suggest potential utility of these nanoparticies for future medical 
applications. This paper describes the development of a new non-radioactive method for assessing serum 
half-life, biodistribution and in vivo stability using the NIRF, CyS.S. This novel method provides 21-
micron histological resolution for identifying populations of cells that bind to the nanoparticies. We 
demonstrate this new technique by analyzing the tissue distribution and serum half-life of a new chitosan-
conjugated nanoparticie. 
Results 
Serum Half-Life of Nanopartic/es 
For assessment of serum half-life, we focused on a reproducible, quantitative assay that utilized 
the NIRF dye, CyS.S, which was incorporated into the nanoparticie. Blood was collected from mice at 1, 
3,6, 10,24, and 48 hours after injection of200 ml of 1 mg/ ml ofNP-chitosan-CTX-CyS.S or the non-
targeted control, NP-chitosan-CyS.S. Blood was centrifuged and the plasma was collected for analysis. 
The blood plasma was added to a 96 well ciear bottom plate and scanned using the Odyssey scanner. The 
CyS.S signal could be readily detected and quantified in small volume blood samples using a 96 well 
format NIR fluorescence scanner as described in the Methods section. NP-chitosan-CTX-CyS.S exhibited 
a longer circulation time than NP-chitosan-CyS.S (Figure 2.1). Exponential decay analysis ofNP-
chitosan-CTX-CyS.S revealed an elimination half-life of 8 hours compared to 7 hours for NP-chitosan-
CyS.S. 
Biodistribution 
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Radioactivity-based pre-clinical biodistribution studies typically fail to show anatomic resolution 
that would distinguish signal differences among subpopulations of cells within a tissue. Likewise, whole 
organ biophotonic imaging for fluorescence-labeled therapeutics also lacks microscopic resolution and 
further suffers from the fact that the quantitative data from whole organs is dramatically affected by size 
and shape of the organ. After demonstrating that the Cy5.5 fluorescent signal is retained after freezing 
(Figure 2.2), we developed an assay in which a NIR fluorescence scanner was used to quantitatively 
assess Cy5.5 signal at 21-micrometer resolution. 
Mice were injected through the tail vein with 200 ml of 1 mg/ml NP-chitosan-Cy5.5 or NP-
chitosan-CTX-Cy5.5. Whole organs were removed 6,24, or 48 hours after injection and scanned using 
the IVIS-lOO imaging system (Figure 2.3A). All tissue was frozen in OCT then sliced in 12-micron 
sections and mounted on glass slides. The slides were scanned on the Odyssey NIR scanner and images 
were obtained using the 700 nm channel (Figure 2.3B). The slice assay revealed, with anatomic 
resolution, small areas within certain organs that bind the conjugate that would be missed by methods that 
involved homogenization or whole organ imaging. For example, signal was present in the wall of the 
aorta in heart slices (Figure 2.4C), but not evident on whole organ imaging (Figure 2.3). While the 
amount of signal is small, the data show the capability of the method to detect small foci ofNIRF-positive 
cells within an organ that otherwise appears to have minimal signal. 
Consistent with whole-organ biophotonic images, significant localization was seen in slices from 
the tissues of the RES (liver, spleen, and bone marrow) as well as the kidneys (Figure 2.3 and 2.4). 
Histological analysis revealed that binding was not uniform in these tissues. The binding patterns in liver 
and spleen suggested macrophage uptake (Figure 2.4). High concentration ofnanoparticles was revealed 
in the spleen white pulp. In kidney, the signal localized to the renal cortex. 
Similar to most nanoparticles, tissue binding was higher in spleen and liver than other tissues. In 
spleen and liver, NIRF signal decreased slightly between hour 6 and hour 48 (Figure 2.5). With the 
exception of bone marrow, in which 4-5 fold increase in signal over background was observed, the signal 
in all other whole organs was statistically indistinguishable from background. There was no significant 
difference in normal tissue biodistribution between untargeted and chlorotoxin-targeted nanoparticles 
indicating that the targeting peptide influences specific binding to tumors (Veiseh et aI., 2009; Pirollo and 
Chang, 2008), but does not affect non-specific binding to normal tissue (Figure 2.5). 
Nanoparticie Stability 
To analyze the stability ofnanoparticle suspensions against agglomeration within the biological 
system, nanoparticles were kept in phosphate buffered saline (PBS) of physiologic pH. No apparent size 
change was observed after incubation ofnanoparticles in media for several months. Nanoparticles were 
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found to be stable with no sign of aggregation or loss of functionality (Veiseh et al., 2009). The stability 
of the CyS.S-nanoparticle-nanoparticle bond upon storage in vivo was confirmed by Pruss ian-blue 
staining for iron oxide nanoparticle core and CyS fluorescent signal in the liver. Colocalization of 
Prussian blue staining and CyS fluorescent indicate that CyS.S fluorophores remain attached to iron oxide 
nanoparticle, confirming the stability of nanoparticles in vivo (Figure 2.6). 
Toxicity Studies 
Guided by the biodistribution data, tissues were carefully evaluated for evidence of nanoparticle 
toxicity. Mice received a single intravenous injection of200 ml of 1 mg/ml ofNP-chitosan-CyS.S or NP-
chitosan-CTX-CyS.S. All mice were evaluated twice weekly for the duration of the studies for clinical 
symptoms of toxicity. None were observed. Seven days after the injection, tissue was removed and fixed 
in 10% formalin. A veterinary pathologist reviewed Hematoxylin and Eosin (H&E)-stained tissue 
sections from liver, spleen, kidney, lung, heart, colon, skeletal muscle, ovary/testes, small intestine, and 
brain of mice injected with control or CTX-targeted chitosan-conjugated nanoparticles (data not shown). 
Despite relatively high levels of nanoparticles in liver, spleen, and bone marrow, no significant lesions 
were observed. In kidneys, mild multifocal tubular abnormalities were observed in subsets of both 
nanoparticle injected and non-injected groups, leading to the conclusion that these mild differences in 
histological appearance were not related to nanoparticle injection. None of the other tissues had abnormal 
findings. Overall, the toxicity studies indicate that the nanoparticles were well tolerated and that renal 
function and renal pathology should be closely monitored if the non-targeted nanoparticles are advanced 
toward clinical use. 
Discussion 
The goal of our approach is to provide rapid and easy monitoring of nanoparticle distribution. In 
the early stages of nanoparticle development, when decisions are being made about materials, coatings, 
synthetic processes and purification, key PK data can be generated in the same mice that are utilized to 
assess nanoparticle targeting to cancer cells or other targets. The stability of nanoparticles is often studied 
in biological media such as PBS and Dulbecco's modified Eagle's medium (DMEM) with 10% offetal 
bovine serum (FBS) (Fang et al., 2009). However, nanoparticles in solutions with physiological salt 
concentration, pH and temperature cannot fully recapitulate different types of cells or immune system in 
biological system. Therefore, we focused on evaluating nanoparticles pharmacokinetic in vivo. In this 
setting, we found that CyS.S signal perfectly matched Prussian Blue staining for the iron oxide 
nanoparticles, indicating exceptional in vivo stability. The PK data can be utilized to inform development 
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and make "go, no-go" decisions. Importantly, serum half-life, biodistribution, and stability are all 
evaluated in the same mice, which reduces the number of research animals utilized (Figure 2.7) and all 
data is generated on a single piece of equipment, which reduces capital equipment costs. 
The serum half-life ofNP-chitosan-CTX-Cy5.5 and NP-chitosan-Cy5.5 is 7-8 hour, which is within the 
ideal therapeutic range. We attribute the prolonged serum half-life to the PEG surface coating with 
chitosan linker, which was designed to reduce nanoparticle agglomeration and the rate of nonspecific 
phagocytosis of the nanoparticles by reticuloendothelial cells. Nanoparticle serum levels in the first 24 
hours, coupled with the biodistribution data, indicate that both liver and kidney are involved in 
nanoparticle elimination. The serum half-life of the tested nanoparticles was in the range that is generally 
considered optimal. 
Biodistribution studies revealed expected localization in kidney, spleen, and liver for both 
targeted and non-targeted nanoparticles. High uptake by mononuclear phagocytic system in the liver and 
spleen are one of the greatest challenges of using nanoparticles for tumor targeting. Our new approach 
allows quantitative measure of nanoparticles distributed in deep tissues of MPS-rich organs with 
anatomical resolution. 
The biodistribution findings have different implications for therapeutics versus imaging. For 
imaging tumor foci, the primary concern is the signal in tumor compared to adjacent normal tissue and it 
does not matter whether other organs have higher signal than the tumor unless they are potential sites of 
metastases or might obscure visualization of the tumor area by emitting bright signal. In contrast, 
targeted therapeutics depends on either having higher targeting to tumor tissue than all other organs that 
might be adversely affected by the therapeutic payload or choosing to deliver a therapy that does not 
adversely affect organs that sequester or excrete nanoparticles nonspecifically. NIR imaging enables 
relatively quick and simple measurements of serum half-life, biodistribution and stability. These data can 
be incorporated into early nanoparticle synthesis decisions as well as more detailed documentation 
required for nanoparticles that are submitted to the FDA for human clinical trials. The data obtained from 
NIR fluorescence imaging provides sensitive, specific, and real-time pre-clinical information that 
complements efficacy studies focused on tumor visualization. 
Materials and Methods 
Nanoparticle Synthesis and Characterization 
Nanopartic1es were synthesized as described previously (Veiseh et aI., 2009). Transmission 
electron microscopy (TEM) has shown the iron oxide cores with a mean diameter of 7 nm. BCA protein 
quantification and fluorescence quantification determined a yield of 16.2 CTX peptides and 1.5 
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fluorophores per nanoparticles on average. 
Serum Half-Life 
All animal studies were conducted in accordance with Fred Hutchinson Cancer Research Center's 
Institute of Animal Care and Use Committee (IACUC) approved protocols as well as with federal 
guidelines. 3-5 month old mice on a C57BL6 background (Charles River Laboratories, Inc.) were 
injected through the tail vein with 200 ml of 1 mg/ml targeted NP-CTX-chitosan-Cy5.5 nanoparticle (n= 
3) or non-targeted NP-chitosan-Cy5.5 control nanoparticles (n= 3). At six different time points after 
injection, 1,3,6, 12,24, and 48 hours, blood was collected by retro-orbital eye bleed or terminal heart 
puncture. Because of limitations on the amount of blood that can be drawn from each animal, no animal 
was used for more than two time points. Blood samples were drawn from three independent mice for 
each time point and frozen at 280uC until analysis. Samples were thawed at room temperature for 30 
minutes prior to analysis. Whole blood was spun using a benchtop centrifuge for 5 minutes at 10,000 rpm 
to separate the plasma. 50 ml of plasma was then added to a 96 well clear bottom plate. The plate was 
scanned on the Odyssey NIR fluorescence imaging instrument (LI-COR, Lincoln, NE) using the 700 nm-
channel (exc = 685 nm with em= 705 nm) to measure Cy5.5 fluorescence signal. Concentration of 
nanoparticles was interpolated from the NP-chitosan-Cy5.5 fluorescence standard curve. A separate study 
was done in advance to ensure that fluorescent signal was not modified by freezing (Figure 2.2). The 
stability of infrared signal during the process of freezing was addressed in a group of mice receiving free 
Cy5.5 dye and CTX-Cy5.5. Mice were injected via lateral tail vein with 100 ml of either Cy5.5 or CTX-
Cy5.S. 24 hours post-injection the animals were euthanized and the kidneys removed. One kidney was 
homogenized in 1 ml of PBS, 30 ml was added to a 96 well plate and the NIRF signal was analyzed using 
the Odyssey imaging system before and after the freezing process. 
Biodistribution of Nanoparticle 
Animals were injected via tail vein with 200 ml of 1 mg/ml NPCTX-chitosan-CyS.S targeted 
nanoparticle, or NP-chitosan-CyS.S non-targeted control nanoparticles. Three additional non-injected 
animals were included as controls. 6, 24, or 48 hours after injection (n= 3) the animals were euthanized 
and tissues were dissected from twelve different organs: kidney, spleen, liver, colon, brain, heart, lung, 
pancreas, muscle, small intestine, gonads, and bone marrow. Bone marrow was extracted by flushing the 
bone marrow cavity with phosphate-buffered saline (PBS) then centrifuged to pellet the marrow. Each 
tissue was imaged using the IVIS-lOO (Xenogen Co., Alameda, CA). Tissues were then embedded in 
OCT and kept frozen at -80uC until needed. The frozen tissues were sliced in 12 mm thick sections and 
mounted onto glass slides. The tissue sections were thawed at room temperature for 30 minutes and the 
16 
fluorescence intensity was measured using the Odyssey fluorescence scanner at a resolution of 21 mm. 
The images were analyzed with the public domain ImageJ software (US National Institutes of Health, 
Bethesda, MD). The average fluorescence intensity was determined for each tissue type using the same 
threshold settings (low threshold: 400, high threshold: 20,000). Data are reported as the average channel 
fluorescence of the tissue, given as relative units after background subtraction. For visual illustrations of 
fluorescence signals, color maps are generated using Matlab (Mathworks, Natick, MA). 
Nanoparticie Stability 
Colloidal stability ofnanoparticles was evaluated by suspending the nanoparticles in PBS media 
of physiologic condition (pH 7.4, 37 /-lC) for several months. For histology and fluorescence imaging 
analysis, 12-mm-thick sections were prepared from the same OCT embedded frozen sample as above. 
Fluorescence imaging of side-by-side non-injected controls and injected liver was performed in the Cy5 
channel (exc = 620-650 nm with em = 680-710 nm) using a TissueFax-System (TissueGnostics, Vienna, 
Austria). The same tissue sections were stained with Prussian blue and nuclear fast red counterstain for 
visualizing iron nanoparticles. Sections were then imaged with TissueFax. 
Toxicity Studies 
Additional Mice were injected with 200 /-ll of 1 mg/ml NPCTX- chitosan-Cy5.5 (n= 3) or NP-
chitosan-Cy5.5 (n= 3) via the tail vein. Seven days after the injection the following organs were 
harvested and fixed in 10% formalin: brain, heart, lung, liver, spleen, kidney, pancreas, gonad, small 
intestine, colon, and muscle. The tissues were paraffin embedded and Hemotoxylin and Eosin stained 
according to standard protocols. Each tissue was analyzed by a veterinary pathologist. 
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(A and B) Standard curve generated by quantifying intensity of known concentrations ofNP-chitosan-
CyS.S or NP-CTX-chitosan-CyS.S. (C and D) Measured fluorescence intensity ofnanoparticles in serum. 
Each data point represents the mean fluorescence intensity integrated above the baseline. This baseline 
subtraction avoids systematic errors from underlying autofluorescence. Error bars represent standard 
errors of the mean. The curve indicates an exponential decay curve fit to the data (n = 3 mice per time 
point). 
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Figure 2.2 Freezing effects on NIRF signal 
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The stability of infrared signal during the process offreezing was addressed in a group of mice receiving 
free Cy5.5 dye and CTX-Cy5.5. Mice were injected via lateral tail vein with 100 ~l of either Cy5.5 or 
CTX-Cy5.5. 24 hours post-injection the animals were euthanized and the kidneys removed. One kidney 
was homogenized in 1 ml of PBS, 30 ~l was added to a 96 well plate and the NIRF signal was analyzed 
using the Odyssey imaging system before and after the freezing process. 
19 
No 
Injection 
Nanopartlcle 
Injection 
A Ex vivo whole organ Imaging 
Figure 2.3 Ex vivo NIRF Imaging of each organ 
)( 
..... 
90 
B Ex vivo 12·mlcron section Imaging 
7000 
6000 
5000 
4000 
3000 
2000 
1000 
Fluorescence image of whole organs in non-injected (top) or NP-CTX-Chitosan-Cy5.5 injected (bottom) 
animals. Images were acquired six hours post injection. (A) Mice were injected 200 III of 1 mg/ml. Six 
hours after injection, the animals were euthanized and the organs were collected. Ex vivo fluorescence 
images of whole organ was obtained using the Xenogen imaging system. The spectrum gradient bar 
corresponds to the fluorescence intensity unit p/sec/cm2/sr. (B) Fluorescence image of 12-micron sections 
obtained using the Odyssey imaging system. The spectrum gradient bar corresponds to relative 
fluorescent level. (Top row: brain, heart, lung, liver, and kidney. Bottom row: pancreas, spleen, small 
intestine, colon, gonad, muscle, and bone marrow) Bone marrow is only shown with the Odyssey scanner. 
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Figure 2.4 Comparison ofH&E staining and high-resolution NIRF fluorescence imaging 
(A) In spleen, NIRF signal was observed in large cells within the white pulp (bar, 500 flm). (B) In liver, 
the pattern was less obvious, but clearly heterogeneous (bar, 500 flm). (C) In heart, the muscle walls of 
the atria and ventricle showed no signal above background but the walls of the aorta showed significant 
signal (bar, 50 flm). (D) In kidney, high NIRF signal was found in the renal cOliex (bar, 1 mm). All 
images were taken of tissues that were harvested 24 hours post nanoparticle injection. 
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Figure 2.S Biodistribution of NP-chitosan-CyS.S and NP-CTX-chitosan-CyS.S nanoparticies 
Relative fluorescence intensity was determined using the Odyssey scanner. Bars represent tissue from 
animals that were not injected with nanoparticles (blue), or injected with nanoparticles and harvested 6 
hours (red), 24 hours (green), or 48 hours (purple) after injection. Bars represent the average of 3 animals 
for each nanoparticle at each time point. The error bars are standard deviation from the mean. (A) Ex vivo 
biodistribution ofNP-chitosan-Cy5.5 non-targeted nanoparticle. (B) Ex vivo biodistribution of NP-CTX-
chitosan-Cy5.5 targeted nanoparticle. 
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Figure 2.6 Co-localization of iron oxide nanoparticle core and Cy5 signal in liver 
No iron uptake or Cy5 fluorescent signal was detected in non-injected control tissue (top row). Co-
localization of Pruss ian blue/hemotoxylin staining and Cy5 signal from the same tissue section suggest 
that the nanoparticles remain stable in vivo (bottom row) (bar, 50 /-lm). 
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Our approach minimizes the number of mice required to evaluate nanoparticle pharmacokinetic 
properties. Serum half-life, whole organ biodistribution, biodistribution at cellular level up to 12 /lm 
resolution, histological and in vivo stability analysis can be performed from the same set of mice that are 
used to assess nanoparticIe targeting to cancer cells or other targets. 
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CHAPTER 3 
Drug resistance mechanisms in mouse medulloblastoma model 
Modified from an article published in PNAS: 
Lee, M.J., Hatton, B.A., Villavicencio, E.H., Khanna, P.C., Friedman, S.D., Ditzler, S., Pullar, B., 
Robison, K., White, K.F. , Tunkey, C. , et al. (2012). Hedgehog pathway inhibitor saridegib (IPI-926) 
increases lifespan in a mouse medulloblastoma model. Proc Nat! Acad Sci USA 109, 7859-7864. 
Summary 
The Sonic Hedgehog (Shh) pathway drives a subset of medulloblastomas, a malignant 
neuroectodermal brain cancer, and other cancers. Small molecule Shh pathway inhibitors have induced 
tumor regression in mice and patients with medulloblastoma; however, drug resistance rapidly emerges, 
in some cases via de novo mutation of the drug target. Here we assess the response and resistance 
mechanisms to the natural product derivative, saridegib, in an aggressive Shh-driven mouse 
medulloblastoma model. In this model, saridegib treatment induced tumor reduction and significantly 
prolonged survival. Furthermore, the effect of saridegib on tumor initiating capacity was demonstrated by 
reduced tumor incidence, slower growth and spontaneous tumor regression that occurred in allografts 
generated from previously treated autochthonous medulloblastomas compared to those from untreated 
donors. Saridegib, a known P-glycoprotein (Pgp) substrate, induced Pgp activity in treated tumors and 
this likely contributed to emergence of drug resistance. Unlike other Smoothened (Smo) inhibitors, the 
drug resistance was not mutation-dependent nor Gli2 amplification-dependent and saridegib was found to 
be active in cells with D473H point mutation that rendered them resistant to another Smo inhibitor, GDC-
0449. The five-fold increase in lifespan in mice treated with saridegib as a single agent compares 
favorably with both targeted and cytotoxic therapies. T he absence of genetic mutations that confer 
resistance distinguishes saridegib from other Smo inhibitors. 
Introduction 
Medulloblastoma is the most common malignant brain cancer in children. While long term 
survival for standard- and high- risk medulloblastoma patients is now greater than 70% and 50% 
respectively, this comes at a significant cost of toxicity due to surgery, radiation, and chemotherapy 
(Rossi et aI., 2008). Shh pathway activation represents about 20-25% of all medulloblastoma cases. Shh 
pathway activation also drives several other types of cancer through cell autonomous oncogenic 
mechanisms or induction of micro-environment properties that provide a growth advantage to tumor cells 
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(Katoh and Katoh, 2009). Therefore, pathway inhibitors are being actively investigated for Shh-driven 
cancers. 
Current therapeutic candidates primarily target the Smoothened (Smo) protein. In normal Shh 
signaling, Smo is released from inhibition by the Patched (Pte h) receptor by surface binding of Shh. Smo 
then activates downstream Shh targets such as the Gli transcription factors. HhAntag, the first synthetic 
small molecule Smo antagonist reported, induces resolution of autochthonous brain tumors and flank 
medulloblastoma xenografts in the Ptchl+/- ;p53-/- mouse model (Romer et ai., 2004). Newer generation 
synthetic small molecules targeting Smo protein are now being used in patients. GDC-0449 was reported 
to induce significant reduction in tumor burden in an adult Shh-driven medulloblastoma patient (Yauch et 
ai., 2009). While these were important first steps toward effectively targeting the Shh pathway in cancer, 
responses were pronounced yet short-lived due to the emergence of drug resistance (Metcalfe and de 
Sauvage, 2011; Rudin et aI., 2009; Yauch et aI., 2009). It remains to be determ ined whether these drugs 
confer a survival benefit to medulloblastoma patients. The identification of Smo inhibitors that remain 
active against cells that develop resistance to other agents in this class could benefit patients, particularly 
if acquired resistance is limited or slower to develop. 
Saridegib is a novel, selective and potent small molecule that targets the Shh pathway by 
inhibiting Smo. Saridegib is orally bioavailable and has demonstrated biological activity in multiple 
preclinical animal models of cancer (Metcalfe and de Sauvage, 2011). In this study we assessed saridegib 
activity in a very aggressive mouse medulloblastoma model, the conditional Patchedl-null (hereafter 
referred to as Ptcc/c), that lacks both alleles of Patchedl (Ptchl) specifically in cerebellar granule neuron 
precursors (Yang et aI., 2008). The Ptcc/cmodel is notable for massive hyperproliferation of granule cells 
throughout the cerebellum and the evolution of highly aggressive tumors that are clinically evident as 
early as P21 and induce death within weeks after mice become symptomatic. 
With few exceptions, targeted therapies have been disappointing in human clinical trials, largely 
due to rapid emergence of resistance mutations. In this study, we evaluated the efficacy ofsaridegib in a 
highly aggressive medulloblastoma model and evaluated drug resistance with particular attention to cell 
autonomous point mutations or amplifications that confer resistance to other agents. Here, we showed 
that drug resistance observed following extended treatment periods is primarily due to increased 
expression and activity of P-glycoprotein (Pgp) drug transporter rather than the emergence of genetic 
mutations that prevent drug-target interactions. 
Results 
Saridegih induces clinical remission and extends survival 
26 
We performed a pilot study to evaluate the efficacy of saridegib in 21-day old Ptcc/c mice with 
clinical evidence of medulloblastoma. Mice were randomized to receive either daily intraperitoneal (IP) 
saridegib (20 mg/kg/dose, n=3) or vehicle (n=2) for 19 days. Full resolution of clinical symptoms was 
evident by 19 days of treatment (Figure 3.1A). In contrast, vehicle treated mice showed progressive 
tumor growth. Analysis of gross tumor pathology following treatment demonstrated a strong response to 
saridegib therapy, with decreased cerebellar tumor size in treated mice (Figure 3.1B). Imaging with 
Tumor Paint (Ctx:Cy5.5), a tumor-tracking molecular bioconjugate (Veiseh et al., 2007), exhibited a 
reduction in tumor burden in saridegib treated mice (Figure 3.1 C) and histopathological analysis of 
cerebellar tumor sections also revealed a decrease in tumor burden (Figure 3.lD). The foliation pattern in 
the cerebellum was completely obliterated in vehicle treated tumors, whereas saridegib treated animals 
manifested regions of tumor cell death, as indicated by pyknotic nuclei with retention of normal cerebellar 
architecture. 
Given these promising results, we performed a larger scale study and extended the duration of 
therapy. Study animals received 6 weeks of daily saridegib (n=26) versus vehicle control (n=l1). Three-
to five-week-old mice with tumors were randomized to receive daily saridegib (20 mg/kg/dose) or 
vehicle. Kaplan-Meier analysis demonstrated that all mice treated with daily saridegib for 6 weeks (red 
line) survived, while all vehicle-treated (blue line) mice developed ataxia and neurologic deficits and 
eventually succumbed to their disease (P< 0.001; Figure 3.2). Clinical symptoms were resolved in many 
of the saridegib treated mice, accompanied by restored neurologic function and increased activity. The 
profound difference between 100% survival and neurologic recovery in saridegib -treated mice compared 
to 100% death in vehicle-treated mice prompted in depth analyses of tumor response. 
Magnetic resonance imaging (MRI) detects sub-clinical disease progression 
Using a technique that preserved intracerebral architecture, histological findings were compared 
to MRI findings in mice that were sacrificed within days of an MRI (Figure 3.3). Histopathological 
evaluation of tumor treated with saridegib for 6 weeks showed reduced tumor volume and a moderate 
reduction in tumor cell density. Extending these findings noninvasively, MRI analyses at 3 week 
intervals showed that saridegib treatment induced substantial tumor regression after three weeks of daily 
administration (Figure 3.4). Hydrocephalus, enlarged ventricles, (yellow arrow) and trans-ependymal 
cerebral spinal fluid (CSF) flow (red arrow) were commonly noted in vehicle-treated mice and were 
minimal in drug-treated mice (Figure 3.4A and Figure 3.5). Mice treated with saridegib showed a 
reduction ofKi67-positive cells in tumor after 4 days of treatment (Figure 3.6), indicating an arrest of cell 
proliferation. Nevertheless, approximately half of the mice treated with saridegib (20 mg/kg/day) 
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exhibited a rebound in tumor growth by 6 weeks following maximal size reduction at 3 weeks (Figure 
3AB-C). 
The MR images were also used to calculate tumor volumes (see Figure 3.3 for representative 
images of 3D-rendered tumor volumes generated from serial MR images). This analysis confirmed the 
significant reduction in tumor volume by 3 weeks ofsaridegib treatment (average tumor volume at 
enrollment = 1108 mm3; average tumor volume after 3 weeks of daily saridegib = 580 mm3; P=0.0005), 
but also showed that not all tumors continued regressing as treatment continued (average tumor volume 
after 6 weeks of daily saridegib = 848 mm3; P=0.05). In contrast, all tumors in vehicle-treated mice 
continued progressing, with average tumor volumes increasing from 1082 mm3 at enrollment to 1408 
mm3 at the 3 week time point. MRI volumetrics were additionally validated by 3D tumor volume 
rendering of serial H&E stained tissue sections from a cohort of mice analyzed by MRI (Figure 3.3). The 
MRI and histological findings prompted two sets of experiments, one to assess the impact of maintenance 
treatment regimens on survival and the other to establish the mechanism(s) underlying disease 
progression during treatment. 
Maintenance saridegib administration prolongs survival 
To further establish the extent to which saridegib can prolong survival, we assessed maintenance 
dosing regimens. Mice were given daily saridegib (20 mg/kg/dose) for six weeks (n=24), and then either 
taken off drug (n=12) or given maintenance dosing (20 mg/kg twice per week) for six additional weeks 
(n=12). Tumors progressed rapidly after the withdrawal of drug following the initial six weeks of daily 
treatment (light purple), resulting in death within an average of 10 days (Figure 3.7A). In contrast, 46% 
of mice receiving maintenance dosing (purple) were still alive six weeks after starting twice-a-week 
therapy. Thus, continued saridegib treatment following six weeks of daily therapy prolonged median 
survival five-fold compared to vehicle treated control animals. Having established tumor regression, 
neurologic improvement and a survival advantage conferred to Ptcc/c mice, we next sought to determine 
whether tumor initiating capacity, which is important for metastases generation, was impaired by drug 
treatment. 
Saridegib reduces medulloblastoma tumor initiating capacity 
Medulloblastoma cells from the PtcClC mice have tumor initiating potential, as evidenced by their 
ability to form new tumors when transplanted to wild type recipient mice. Tumors were established from 
9 of 11 drug-naIve donors and 43% (54 out of 127) of recipients grew flank tumors. In contrast, the same 
approach yielded tumors in only 23% (18 out of 78) of recipients when donors were treated with daily 
saridegib for 6 weeks (20 mg/kg) prior to transplantation (Figure 3.7B). This demonstrated that saridegib 
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reduced tumor initiating potential in this aggressive medulloblastoma mou,Se model when transplanted in 
flank (P=0.017) . Interestingly, the tumor growth rate in saridegib treated donor allografts differed from 
that of the drug naIve donor group. Flank allografts established from the drug treated donor group grew 
much more slowly and often stopped growing. One out of six tumors showed spontaneous tumor 
regression in the absence of drug after initial growth to 895mm3. 
Saridegib induces regression of flank allografts from drug refractory donors 
To explore whether the resistance was through cell-autonomous mechanisms, we used the 
allograft models to investigate the effect of saridegib treatment on tumor size. When the flank allograft 
tumor volumes reached 1000 mm3, recipient mice received either daily saridegib (20 mg/kg) or vehicle 
treatment and the growth of flank allografts was monitored over a nine-week period. Daily IP 
administration of saridegib into recipient mice suppressed tumor growth to the point that tumors were 
undetectable in 100% of both allograft groups (Figure 3. 7C). We attribute the response of flank tumors 
derived from the saridegib -treated donor mouse to higher drug concentrations in the flank tumors 
compared to brain tumors, the latter of which are protected by the blood brain barrier. Consistent with 
this, saridegib concentrations were approximately 10-15 fold higher in flank tumors than in cerebellar 
tumors at the same dosing regimen (Table 3.1). Interestingly, the markedly higher drug concentrations 
achieved in flank tumors were sufficient to overcome the drug tolerance observed in the cerebellar tumor 
of the donor mouse. However, the higher concentration alone was not sufficient to sustain remission in 
mice that received flank allografts from drug-naIve donors. Two of five tumors progressed while on 
therapy during the 9-week trial despite initially disappearing in response to saridegib administration. 
Escape from Shh inhibition accompanies tumor progression in saridegih treated mice 
To better understand drug engagement with Shh pathway activity after prolonged treatment, we 
assessed the level of Glil inhibition by saridegib at the end of 6 weeks of daily therapy. Reduced 
suppression of Shh signaling at the end of therapy would indicate the emergence of saridegib-resistant 
cells. This possibility was supported by the observation that saridegib suppressed Glillevels by 83% 
after 4 days of daily treatment, by 52% after 2 weeks of therapy and by 29% after 6 weeks of therapy, 
respectively, compared to that of vehicle treated control tumors (Figure 3.8A). The blood brain barrier 
has been shown to limit drug penetration into the brain over time through induction of drug efflux pumps 
(Loscher and Potschka, 2005). This was not the case in our study, as saridegib concentrations increased 
in cerebellar tumors over time (Table 3.1). 
Pgp-mediated efflux transport 
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One of the main mechanisms of drug resistance in cancer cells is aberrant expression of ATP-
binding cassette (ABC) transporters, which utilize active transport to efflux drugs from treated cells. 
Many chemotherapeutic drugs and Shh inhibitors are substrates of the ABC transporter Pgp. To 
determine whether Pgp was up-regulated in response to saridegib therapy, we quantified Pgp transporter 
expression via Western blotting in samples from vehicle treated and saridegib treated mice. The 
expression levels of Pgp in tumor homogenates were significantly increased by daily treatment with 
saridegib for six weeks (Figure 3.8B). We compared the function ofPgp in untreated and saridegib-
treated medulloblastomas using calcein-AM, a fluorescent Pgp substrate that quantitatively measures Pgp 
activity. Intracellular accumulation of calcein in untreated and saridegib treated mice was measured by 
flow cytometry. 79.5% of vehicle treated tumor cells incorporated calcein as compared with only 38.6% 
of accumulation in saridegib treated PtcClC tumors (Figure 3.8D). The experiment was repeated in the 
presence of the Pgp inhibitor, verapamiI. Increase in the intracellular level of fluorescence after exposure 
to verapamil indicates the presence ofPgp transporters in saridegib treated Ptcc/c (Figure 3.8C). 
To determine whether Pgp inhibition influenced the affect of saridegib on Gli 1 expression, we 
measured Glil levels in the presence of the Pgp inhibitor, verapamil, and saridegib. Indeed, inhibition of 
Pgp transporter via verapamil treatment reversed drug resistance, suggested by decreased Glil levels 
within tumors receiving the combined therapy (Figure 3.8A). 
Lack of resistance-inducing mutations or Gli amplification 
Previous studies revealed that Smo activating or drug resistance point mutations occur in the sixth 
(TM6) or seventh (TM7) transmembrane domains (Taipale et aI., 2000; Yauch et aI., 2009). In contrast, 
tumors that grew despite ongoing saridegib therapy showed no evidence of mutations in TM6 or TM7. 
Of the 8 brain and 3 flank tumors from which the Smoothened gene was sequenced, only one showed 
sequence variations that could not be readily attributed to known inter-strain single nucleotide 
polymorphisms. This point mutation at Asparagine 223 is not within any of the seven transmembrane 
domains of the Smo protein and does not map to a region of the protein with a known functional domain. 
We conclude that it is unlikely that the re-growth of both intracranial and flank allografted 
medulloblastomas is dependent on de novo Smoothened mutations. 
A recent report showed that point mutations were found only infrequently in tumors that 
developed resistance to the Smo inhibitor, NVP-LDE225, but Gli2 amplifications were observed in 50% 
of resistant tumors (Buonamici et aI., 2010). PCR analyses of genomic DNA from 8 saridegib resistant 
brain tumors revealed no Gli2 amplification. Thus, the cell autonomous genetic events that lead to 
resistance to GDC-0449 and NVP-LDE225 were not present in saridegib-treated medulloblastoma 
tumors, indicating that this cyclopamine derivative interacts with the target protein in a manner distinct 
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from the synthetic Shh inhibitors. Furthermore, comparative genomic hybridization (aCGH) showed no 
focal gains or losses across the entire genome of saridegib-treated tumors compared to normal. 
Expression profiling of saridegih treated tumor showed minor changes in Shh pathway signatures 
We used Illumina microarray to validate mRNA expression signature ofvehic1e and saridegib 
treated tumors. We identified several networks/pathways that were statistically significantly enriched, 
including those involved in caner, neurological disease, cell death, and cellular movement using Ingenuity 
Pathway Analysis (Table 3.2). Top most differentially expressed genes are listed in Table 3.3. We 
examined the level of llgene SHH subgroup signatures: butyrylcholinesterase (BCHE); GLIl; GLI2; 
inter-a-trypsin inhibitor heavy chain H2 (ITIH2); microtubule-associated monoxygenase, calponin and 
LIM domain containing 1 (MICALl); PDZ and LIM domain 3 (PDLIM3); PTCH2; RAB33A; secreted 
frizzled-related protein 1 (SFRPl); orthodenticle homeobox 2 (OTX2); and neurogenin 1 (NEUROG l). 
Recurrent tumors showed characteristics of Shh subgroup similar to vehicle treated group (Figure 3.9). 
Among those genes, secreted frizzled-related protein 1 (SFRPl) and Orthodenticle homeobox 2 (OTX2) 
showed statistically significant differential expression in drug treated group compared to that of vehicle 
treated group. 
Saridegih activity on D473H SMO mutant 
Saridegib was assayed alongside other Smo inhibitors in the C3Hl 0 differentiation assay as 
previously described (Tremblay et aI., 2009). Saridegib and inhibitors GDC-0449, LDE-225 and SANT-l 
all have activity in the 7-30 nM ECso range. Cyc10pamine is less potent with an ECso range of 500 nM-
ImM. To determine the ability ofsaridegib to suppress Shh signaling in the context of the D473H 
SMOOTHENED (SMO) mutant known to confer resistance to the Shh pathway antagonist GDC-0449 
(Yauch et aI., 2009), we measured the half maximal concentration (ICso) of saridegib required to inhibit 
Gli-Iuciferase activity (Figure 3.7D). Saridegib inhibited reporter activity at an ICso of9nM in 
C3HIOTl/2 cells transfected with wild type SMO and also showed activity against the D473H SMO 
mutant at an ICso of244nM. Saridegib induced greater than 95% inhibition at 1 !AM concentration in 
D473H SMO mutant cells, which compares favorably with GDC-0449 (3% inhibition at 1 !AM 
concentration), cyc10pamine (the parent drug from which saridegib is derived, 48% inhibition at 1 !AM 
concentration) and other drugs screened for activity against this mutation (Dijkgraaf et aI., 2010). These 
findings are in contrast to results obtained with other hedgehog pathway antagonists and suggest that 
saridegib retains the ability to impair downstream hedgehog signaling even in the presence of some 
activating SMO mutations. 
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Discussion 
Medulloblastoma is an aggressive malignant brain cancer that is particularly difficult to cure in 
the recurrent disease setting. Conventional therapies for medulloblastoma impose unacceptable toxicities 
on children with this disease and more effective, less toxic alternatives are critical for future care. Smo 
inhibitors show promise for targeting Shh-driven tumors, but resistance emerges rapidly (Dijkgraaf et aI., 
2011; Rudin et aI., 2009; Yauch et aI., 2009). Because this pathway is considered crucial for several 
cancer types, efforts are underway to advance drugs that are less prone to resistance induction. 
In this study, six weeks of daily saridegib resulted in 100% survival compared to 0% in the 
vehicle-treated medulloblastoma-bearing mice. Additionally, a substantial resolution in clinical 
symptoms was observed in the majority of saridegib treated mice, secondary to reduced hydrocephalus, 
calvarial swelling and accompanied by increased mouse activity. Treatment with saridegib sharply 
reduced tumor allograft engraftment success and some allografts established from saridegib donors 
underwent spontaneous regression after initial significant growth. Both observations are consistent with 
the notion that Smo inhibitors limit medulloblastoma tumor initiating capacity. 
This is the first study to examine hedgehog pathway antagonism in the conditional PtcC/C mice. A 
previous study demonstrated the efficacy of the HhAntag hedgehog antagonist in a less aggressive 
Ptchl+I-;p53-1- model of medulloblastoma arising in the Ptchl heterozygous,p53 null background (Romer 
et aI., 2004). While these results share similarities to our current study, an important contrast must be 
noted in the extent of tumor burden in response to heterozygous versus homozygous loss of Patchedl 
within the cerebellum. In the PtcC/C model, all cerebellar granule neuron precursor cells are lacking the 
inhibition normally mediated by the Patched1 receptor, and tumor formation is early, aggressive and 
uniform throughout the cerebellum. Thus, the response to saridegib was remarkable given the continuous 
source of neoplastic cells and the extent of initial tumor burden in intracranial PtcC/C tumors. 
The heptahelical structure of the Smo receptor is required for binding of cyclopamine and is 
targeted by G protein coupled receptor modulators (Chen et aI., 2002) and mutations near the highly 
conserved transmembrane domains can reduce the affinity of compounds specifically targeted to this 
binding pocket. In contrast to the previous report of mutation-based resistance to GDC-0449, we did not 
observe mutations in the TM6 or TM7 domains of the Sma allele, nor did we observe Gli2 amplification. 
Gene expression profiling suggests minor alteration of two Shh signature genes in the saridegib-
treated group. We found downregulation ofSFRP1 genes and up-regulation ofOTX2. Previously, 
SFRP1 has been identified as a prime biomarker for the Shh subgroup (Northcott et aI., 2011), and a high 
expression level ofSFRPl was found in Ptch1+1- tumors (Pei et aI., 2012). The expression ofOTX2 is 
low or absent in Shh-driven human medulloblastoma (Di et aI., 2005; Adamson et aI., 2010). OTX2 copy 
number gain has been associated with more aggressive tumor phenotypes and decreased patient survival 
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(Adamson et aI., 2010), and inhibition ofOTX2 in medulloblastoma cell lines decreased tumor 
proliferation and formation in vitro (Bunt et aI., 2010). Although OTX2 is an essential gene in Shh-
independent medulloblastoma, little is known about its role in Shh-dependent medulloblastoma and its 
mechanism by which OTX2 regulates the expression of its target genes. Given that OTX2 is upregulated 
in saridegib resistant tumor, it will be important to perform detailed molecular studies of oncogenic 
pathways driven by OTX2. These studies will aid the development of new therapeutic strategies for Shh-
independent medulloblastoma patients as well as Shh-dependent patients who develop resistance against 
Smo therapy. 
The absence of genetic mutations in Sma or amplifications of Gli2 raise the question of why 
tumors eventually grow in mice treated with saridegib. It is possible that this is a reflection of the highly 
aggressive model, in which most cells in the granule cell lineage completely lack negative regulation of 
the mitogenic Shh pathway. Alternatively, saridegib activity could be affected by common drug 
resistance mechanisms such as ABC transporters. Indeed, we saw increased Pgp expression in the brain 
tumors of mice treated for 6 weeks with saridegib (Figure 3.8). Furthermore, co-administration of 
verapamil, a Pgp inhibitor, partially restored the capacity of saridegib to reduce G li 1 even after extended 
(6 week) treatment periods. A Pgp functional assay with calcein-AM revealed increased level of efflux 
activity in saridegib treated Ptcc/c. The relationship between Pgp and saridegib activity is somewhat 
confusing because the binding site of cyclopamine, and presumably the cyclopamine derivative saridegib, 
lies on a portion of Smo that is internal to the plasma membrane. In addition, it is not clear whether the 
drug accesses the binding site from the cytoplasmic side or the surface of the plasma membrane. 
Unlike studies of other oncology drugs, including cytotoxic chemotherapy agents, our results are 
unique because they show a fivefold increase in survival in mice with advanced, aggressive, 
autochthonous brain tumors. Our nonclinical studies clearly demonstrate the efficacy of saridegib in 
resolving clinical symptoms of advanced medulloblastoma and prolonging survival in the Ptcc/c model. 
Materials and Methods 
Mouse Models and Drug Dosing 
Animal experiments were conducted in accordance with the NIH and Institutional guidelines. 
Conditional Patchedi null mice (Ptcc/c) were generated by breeding mice homozygous for the 
floxedPtchi allele (Adolphe et aI., 2006) to Mathi-Cre mice (Yang et aI., 2008). For allograft studies, 
medulloblastomas from symptomatic Ptcc/c mice were harvested, triturated, filtered, and resuspended in 
equal parts ofDMEM and Matrigel (BD Biosciences). lxl06 cells were injected subcutaneously into the 
flank of wild type littermates. Tumor volume was calculated from caliper measurements (0.5 x length x 
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width2). Postnatal day (P) 21 to P36 Ptcc/c mice were randomized to receive either saridegib (Infinity 
Pharmaceuticals; 20mg/kg/dose) or vehicle control (5% (2-Hydroxylpropyl)-J3-Cyclodextrin (HPBCD), 
Sigma-Aldrich) administered via daily intraperitoneal (IP) injection. Saridegib drug levels in tumor and 
brain samples were determined as previously described (Olive et al., 2009). For combination therapy, 
ABC transporter inhibitor verapamil (Sigma-Aldrich; 15mg/kg/dose) was administered weekly via oral 
gavage between third and sixth week. 
Tumor Pathology 
We preserved tissue while maintaining the spatial integrity of the brain and ventricular spaces 
within the skull. Whole brains within the skull were fixed in 10% formalin, decalcified using F ormical 4 
(Decal Chemical) and embedded in paraffin. Tissues were cut into 4!!m sections in the horizontal plane 
and H&E stained to generate computerized three-dimensional (3D) renderings of the tumors. Sections 
were scanned using a TissueFax microscope (TissueGnostics), stacked and aligned using the StackReg 
function of ImageJ and 3D models rendered using Imaris. 
Magnetic Resonance Imaging and Cholorotoxin: Cy5.5 (Ctx:Cy5.5) Imaging Analysis 
Magnetic resonance imaging (MRI) was performed using a 3 Tesla MRI system (Philips 
Achieva) and a custom mouse head coil. Serial MR scans were performed under halothane anesthesia 
using a 35 minute coronal high-resolution T2-weighted sequence (TE=llOms, TR=2000ms, 
bandwidth=212, 2 NEX or signal averages, pixels in-plane=256x256, slice thickness=320!!m, interslice 
gap=160""m). DICOM images were exported from the MRI scanner to a web-based repository 
(BioScribe) and then imported into ITK-SNAP (www.itksnap.org). Ctx:Cy5.5in vivo imaging was carried 
out as previously described (Veiseh et al., 2007). 
Gene Expression Analysis 
Total RNA was extracted (RNeasy Plus Kit, Qiagen) and converted to cDNA (Taqman Reverse 
Transcription kit, ABI). Quantitative RT-PCR was performed using Taqman Master Mix and the 
7300HT System (AB!) using Taqman primers for mouse Gliland Gapdh and SDS2.3 software (ABI). All 
conditions were run in triplicate and normalized to mouse Gapdh controls. 
For whole-genome expression analysis, RNA was hybridized to mouse-specific (MouseWG-6 
v2.0) expression BeadChips (Illumina). Probe intensities were normalized with the Illumina specific Lumi 
Bioconductor R package. Functional gene-interaction network analysis was performed by using Ingenuity 
Pathways Analysis (Ingenuity Systems). 
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Gene Amplification Analysis 
Gli2 amplification was assessed by Real Time PCR using SYBR green PCR kit (Qiagen). Tumors 
were snap frozen and analyzed for Gli2 using three different primer sets and for GAPDH has 
normalization control. Genomic DNA from 4 mice of different genomic backgrounds was used as 
controls for each assay along with a no template control. Four technical replicates were performed. 
Western Analysis 
Tumor samples were homogenized in RIP A lysis buffer, which included protease inhibitors. 
Equal amounts of proteins were loaded onto 4-12% SDS-PAGE gel, transferred onto PVDF membrane, 
and probed with the antibody of interest: Pgp (C219; 1 :100; Covance). 
Immunohistochemical Staining 
Tissues were cut into 4-J..lm sections and immunostained with the following antibodies: anti-Ki67 
(1: 1,000; Novocastra) and anti-Cleaved Caspase 3 (1 :50; Biocare Medical). Sections were scanned with a 
TissueFax microscope (TissueGnostics). For Ki67 and Cleaved-Caspase 3 staining quantification, 
positive staining was quantified with National Institutes of Health image analysis software, Image J, and 
reported as percentage area of staining in the cerebellum. 
DNA Sequencing Analysis 
Frozen tumor samples were lysed in a Geno/Grinder 2000 (SPEX CertiPrep) followed by DNA 
isolation using a QIAamp DNA mini kit (Qiagen). Samples were quantitated with a Nanodrop 2000c 
(Thermo). PCR primers were tagged with M13F forward (TGTAAAACGACGGCCAGT) or M13 reverse 
(CAGGAAACAGCTATGAC). Information on primer sequences for SMO exons 1-12 is provided in 
Table 3.4. PCRs were run on a Dyad DNA Engine (MJ Research/Bio-Rad) using the following 
conditions: 95°C 5 min followed by 35 cycles of 95°C 30 s, 60°C 30s, 68°C 45 s, followed by 68°C 10 
min. Target sequence was sequenced by the Sanger method (Gene Wiz) in both forward and reverse 
directions. 
Gli-Luciferase Reporter Assay 
Gli-Luciferase reporter assays were performed as described (Yauch et aI., 2009) 
Gene Expression Analyses 
Purified total RNA was hybridized to mouse-specific (WG-6 v2) expression beadchips (Illumina). 
Probe intensities were normalized by the Illumina specific Lumi Bioconductor R package. Functional 
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gene interaction network analysis was perfonned using Ingenuity Pathways Analysis (Ingenuity 
Systems). 
Array Comparative Genomic Hybridization 
Genomic DNA was labeled and hybridized to Mouse Genome 244K array-CGH (Agilent 
Technologies) using WT littennate genomic DNA as a reference. Arrays were scanned with an Agilent 
microarray scanner and image analysis was perfonned using Agilent Feature Extraction software. 
Pgp Functional Assay by Flow Cytometry 
Pgp functionality was assessed by measuring fluorescent dye efflux of calcein-AM (Molecular 
Probes) with or without Pgp inhibitor, verapamil. 5 x 105 cerebellar PtcClC tumor cells were incubated with 
or without lOJlM verapamil for Ihr at 37°C. Then cells were incubated with non-fluorescent IJlM 
Calcein-AM for another 30 min at 37°C. Cells were washed and resuspended in cold PBS and analyzed 
for calcein fluorescence by flow cytometry (Excitation: 495nm; emission: 515nm). Debris was 
eliminated by gating on forward versus side scatter. The function of Pgp is expressed as the mean 
percentage of fluorescence intensity of gated FITC positive cells. The assays were perfonned in triplicate. 
Statistical Considerations 
Studies were designed to detect differences in event rates that approximately corresponded to a 
doubling of median improvement in survival of (3 weeks) with 90% power based on simulated power 
experiments. These estimates were made using two-sided log-rank test at P<0.05 significance level. 
Survival analyses used animal death times and censoring times when animals were sacrificed at 
approximately 6 weeks or as otherwise stated. Survival curves were plotted using Kaplan-Meier method 
and compared using two-sided log-rank test. The Bonferroni test was used to correct multiple 
comparisons. Statistical analyses were perfonned in R statistical systems (http://www.r-project.org). 
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Figure 3.1 The Smo inhibitor saridegib causes regression of mouse medulloblastoma 
Three-week old mice symptomatic for medulloblastoma were randomized to receive daily intraperitoneal 
saridegib (20 mg/kg/dose, n=3) or vehicle (n=2) for 19 days. (A) Compared to a representative vehicle-
treated mouse with a large tumor (left panels) and a wild-type littermate with no tumor (right panels), a 
representative mouse treated with saridegib (center panels) showed complete resolution of clinical 
symptoms after 19 days of saridegib treatment. The arrow in denotes the bulging skull caused by tumor. 
(B) A response to saridegib was apparent by gross pathology, (C) imaging with Tumor Paint (Ctx-CyS.S), 
and (D) H&E staining. 
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Figure 3.2 Saridegib improves survival in the PtcC/c medulloblastoma model 
Kaplan-Meier analysis demonstrates that all Ptcc/c mice receiving daily saridegib (20mgikg, red line) 
survived, while all vehicle-treated mice (blue line) succumbed to their disease prior to the six-week time 
point (P<O.OOl). 
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Figure 3.3 3D tumor volume rendering and analysis of pathology 
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Image panel summarizing a comparison of tissue sections from brains processed outside of (leftmost 
column) or from within the skull (second column) and the related H&E-based 3D renderings (third 
column) of cerebellar or tumor volume. H&E-based 3D tumor models are matched to the MRI-generated 
volume model for the same sample (rightmost column). 
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Figure 3.4 MRls demonstrate decreasing tumor volumes during saridegib administration 
(A) A representative T2-weighted MR image demonstrates the enlarged ventricles (yellow arrow) and 
trans-ependymal cerebral spinal fluid (CSF) flow (red arrow) resulting from cerebellar tumor progression 
in a vehicle treated mouse. Saridegib treated mice demonstrate a significant reduction in ventricle size and 
a resolution of trans-ependymal CSF flow. (B) Tumor volume was estimated from MR scans taken at 
enrollment, after 3 weeks, and 6 weeks of treatment Representative images of 3D reconstructed tumors 
are shown, with an untreated wild-type cerebellum displayed for reference (shown in yellow). (C) Tumor 
volumes (mm3) were estimated at each time point for vehicle treated (n=5) and Saridegib treated Ptcc/c 
mice (n=7). None of the vehicle-treated mice survived until the 6 week imaging time point 
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Baseline at Enrollment 3 Weeks Vehicle 
Baseline at Enrollment 3 Weeks IPI-926 6 Weeks IPI-926 20 Days OFF IPI-926 
Figure 3.5 Monitoring tumor response via MRI 
(A and C) Representative MRI scans in the sagittal plane from vehicle-treated (A) or saridegib-treated 
(C) Ptcc/c mice are shown at enrollment, after 3 wk of daily saridegib treatment, after 6 wk of daily 
saridegib treatment, and after drug withdrawal. T2-weighted axial images were acquired at 3 T with a 
Philips MRI system and a custom mouse-head coil. Control mice were imaged at enrollment and after 3 
wk on daily vehicle treatment, although no vehicle-treated mice survived until the 6-wk imaging time 
point. (B and D) Live animal images are shown in parallel with the MRI scans for vehicle-treated (B) and 
saridegib-treated (D) mice.Saridegib maintenance administration prolongs survival in medulloblastoma 
mice 
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Figure 3.6 Effect of saridegib on proliferation and apoptosis 
Representative examples of immunohistochemical analysis ofPtcc/c tumors stained with Cleaved Caspase 
3 (A) and Ki67 (B) antibodies are shown. Percentage area of active Caspase 3 and Ki67 were quantified 
with Image J. Compared with vehicle-treated controls, mice treated with the saridegib (20 mglkg) show 
reduced expression ofKi67 and increased Cleaved Caspase 3 staining after 4 d of treatment. The effect of 
the drug on apoptosis and proliferation was reduced after 6 wk of daily therapy. Verapamil and saridegib 
combination therapy resulted in similar apoptotic and proliferative responses compared with saridegib 
alone. (Scale bars: Upper, 1 mm; Lower, 50 Ilm.) Individual data points represent the means ± SEM of 
three independent samples from each treatment. 
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Figure 3.7 Saridegib maintenance administration prolongs survival in medulloblastoma mice 
(A) Three- to five-week-old Ptcc/c mice symptomatic for medulloblastoma were randomized to receive 
vehicle (blue line) or saridegib. Mice were initially given daily saridegib (20 mg/kg/dose) for six weeks 
(n=24), and were then taken off the drug (n=12; light purple line) or given maintenance dosing (20 mg/kg 
twice per week) for six additional weeks (n=12; purple line). Daily saridegib followed by twice weekly 
dosing provided a significant survival benefit compared to vehicle controls (P<O.OOI) and to mice taken 
off drug (P=O.OOI). (B) Flank allografts were established in 43% of recipients from drug-naIve Ptcc/c 
donors. Only 23% of recipients developed flank tumor when donors were treated with saridegib daily for 
6 weeks (20 mg/kg) prior to transplantation. (C) Recipient mice bearing drug-naIve and saridegib treated 
allograft tumors were then treated with daily saridegib (20mg/kg). Dotted line indicates beginning of 
treatment. Tumors were undetectable in both allograft groups by day 15. Two of five tumors became 
unresponsive during the 9-week trial despite initial response to saridegib. (D) The average Gli-Iuciferase 
reporter activity was measured in C3HlOTl/2 cells transfected with wild type SMOOTHENED (SMO) 
(squares) or the D473H SMO mutant (triangles) after treatment with various doses of saridegib. Saridegib 
inhibited reporter activity at an IC50 of9nM in C3HlOTl/2 cells transfected with wild type SMO and also 
showed activity against the D473H SMO mutant at an IC50 of 244nM. Reporter activity is normalized to 
untreated C2HI0Tl/2 cells. (Error bars, SEM) 
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Figure 3.8 Mechanisms of resistance in saridegib treated Ptcc/c tumors 
(A) The pharmacodynamic activity of saridegib in Ptcc/c tumors was confirmed by analysis of GliI 
mRNA by RT -PCR. Result shows a substantial decrease in Gli 1 expression after 4 days of saridegib 
treatment (P=O.05). The initial reduction in GliI expression seen in response to daily saridegib 
(20mg/kg/dose) was diminished after 6 weeks of therapy. Drug resistance to saridegib was partially 
reversed by co-treatment with Pgp inhibitor verapamil. Bars represent the average fold change in Glil 
expression normalized to vehicle-treated controls (n=3 per group; error bars = SEM). (B) The expression 
ofPgp was quantified via Western blot at enrollment, after 4 days, and 6 weeks of treatment. Bars 
represent the average fold change in Pgp normalized to Gapdh (n=3 per group). Error bars, SEM. (C) 
Efflux activity of Pgp in saridegib treated Ptcc/c was evaluated by measuring the intracellular 
fluorescence of calcein with flow cytometer. Compared to vehicle controls, saridegib treated tumors had 
lower calcein accumulation. Inhibiting the Pgp activity with lOOI!M verapamil increased calcein 
fluorescence as indicated by small shift of peak to the right. Gray line indicates autofluorescence of the 
cells that were not exposed to calcein-AM. (D) Percentage of cells appears within FITC positive gate was 
quantified. Pgp-mediated efflux activity was significantly increased in Ptcc/c tumors treated with 
saridegib (n=3 per group; error bars = SEM). 
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Figure 3.9 Differential gene expression in vehicle- and saridegib-treated PtcClC samples 
(A) Three independent vehicle- and saridegib-treated PtcClC samples were analyzed with the use of an 
Illumina expression array. The heat map depicts the expression of the Sonic Hedgehog (Shh) signature 
genes. (B) Differentially expressed Shh signature genes highly expressed in vehicle-treated compared 
with saridegib-treated PtcClC samples. (C) Differentially expressed Shh signature genes highly expressed 
in saridegib-treated compared with vehicle-treated PtcClC samples. 
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Tissue concentration 
Genotype Treatment Statistics Cerebellumttumor, ng/g Forebrain, nglg Plasma, ng/mL 
WT None Mean 0 0 0 
SO 0 0 0 
Sarideglb for 4 d, daily, Mean 482 393 652 
20 mgllcg per dose SO 75 84 276 
Ptcc/c intracranial None Mean 0 0 0 
tumors SO 0 0 0 
Sarideglb for 4 d, daily, Mean 478 300 803 
20 mgllcg per dose SO 98 32 316 
Sarideglb for 6 wk, daily, Mean 1,269 376 1,135 
20 mgllcg per dose SO 570 58 411 
Sarldeglb for 3 wk, dally, Mean 5,956 1,659 1,830 
20 mg/kg per dose; SO 2,302 421 349 
one dose at 70 mgllcg 
Saridegib for 3 wk, daily, Mean 8,911 1,569 2,553 
20 mg/kg per dose; 3 wk, SO 1,726 469 501 
one dose per week, 70 mg/kg 
Pt~ flank allografts None Mean 0 N/A NIl 
(WT recipients) SO 0 NlA N/A 
Saridegib for 7 d, daily, Mean 47,320 NlA N/A 
20 mgllcg per dose SO 27,887 NlA N/A 
Saridegib, daily, 20 mgllcg Mean 22,053 N/A N/A 
per dose until tumor regrowth SO 3,834 NlA N/A 
NlA, not applicable. 
Table 3.1 Drug concentrations in plasma, brain and tumor 
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No. of Genes down-regulated 
Category P molecules Genes up-regulated by more than twofold by more than twofold 
Cancer 2.19 x 10-2 '_1.04 x 10-0• 173 MT1E, ANXAS, TIMP1, IFITM3, PlEKHB1, EFF1A2 CHRNA3, MTDH 
Neurological 6.03 x 10-25-8.09 x 10-04 159 C3, SPP1, PDGDS, VSNL1, EN02, PVALB, OTX2, CHRNA3, MTDH 
disease CH13l1, ITPR1, PCP2, LCN2, THY1, DCN, SLC24A2, 
C4B, MBP, IGFBP5, ATP2A3, HSPBS 
Skeletal and 7.15 x 10-25-1 .24 x 10-0· 154 C3, SPP1, PDGDS, VSNl1, EN02, PVALB, CH13l1, CHRNA3, MTDH 
muscular disorders ITPR1, lCN2, THY1, C48, MBP, IGFBPS, ATP2A3, HSP88 
Cell death 1.27 x 10-19-1 .29 x 10-0 • 140 LGALS3, C3, HBB, HBA1IHBA2, SPP1, PTGDS, CALB2, MTDH 
0TX2, CH13l1, ITPR1, LCN2, lyzllLy>2, THY1, DCN, 
MBP, IGFBPS, GADD4SG, HSP8S, PCSK9, GFAP 
Cellular movement 9.06 x 10-15-1 .26 x 10-0· 96 LGALS3, 0, SPP1, VSNl1, CH1311, ITPR1, LCN2, Ly>lllyz2, 
THY1, DCN, C4B, IGFBP5, RASGRF1, GFAP 
Cellular growth 2.13 x 10-14-1.08 x 10-0· 136 lGALS3, C3, SPP1, GPNMB, PTGDS, OTX2, ITPR1, LCN2, 
and proliferation THY1, DCN, MBP, IGFBPS, GADD4SG, HSPB8, 
RASGRF1, GADI 
Tissue development 1.IS x 10-13-1.04 x 10-0· 126 LGAlS3, C3, HBB, HBA1IHBA2, SPP1, PTGDS, VSNll, CHRNA3 
0TX2, KNDC1, ITPR1, lCN2, ATP1Bl, THY1, DCN, C4B, 
MBP, IGFBP5, GADD4SG, RASGRP1,PC5K9, GFAP 
Nervous system 2.55 x 10- 11-1.26 x 10-0· 96 0, HBA1IHBA2, VSNl1, OTX2, CHI311, KNDC1, ITPR1, CHRNA3 
development ATP1Bl, THY1, 5LC24A2, MBP, RASGRP1,PCSK9, GFAP 
and function 
Hematological system 2.46 x 10-10_1 .24 x 10-0· B9 LGALS3, C3, HBB, HBA1IHBA2, SPP1, PTGDS, CHI3Ll, 
development and LCN2, LyzlILyz2, THY1, DCN, C4B, MBP, GADD4SG, 
function HSPBS, GFAP, GJAI 
Immune cell 2.46 x 10-10_1.24 x 10-0· 64 LGALS3, C3, SPP1, PTGDS, CHI3Ll, LCN2, LyzllLyz2, THY1, 
trafficking DCN, C4B, MBP, HSPB8, GFAP, ANXAS, NBL1, TlMPl 
Genes from the dataset that met the log·ratio cutoff of ~ :O.5i and P < 0.05 were considered for the analysis. 
Table 3.2 Top 10 networks of the genes significantly altered in saridegib treated PtcClC tumor 
Genes from the dataset that met the log ratio cutoff of:=:: 10.51 and P value <0.05 were considered for the 
analysis. 
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Symbol Entrez gene name Log ratio P 
Log ratio up-regulated 
LGALS3 Lectin, galactoside-binding, soluble, 3 2.232 1.56 x 10-16 
C3 Complement component 3 2.072 6.61 x 10-16 
HBB Hemoglobin, jJ 2.000 6.62 X 10-09 
HBA1/HBA2 Hemoglobin, a1 1.741 2.07 x 10-08 
SPP1 Secreted phosphoprotein 1 1.736 3.12 x 10-10 
GPNMB Glycoprotein (transmembrane) NMB 1.705 1.34 x 10-12 
PTGOS Prostaglandin 02 synthase 21 kOa (brain) 1.687 6.73 x 10-13 
CALB2 Calbindin 2 1.612 7.28 x 10-13 
VSNL1 Visinin-like 1 1.535 1.98 x 10-13 
ITIH3 Inter-(x-trypsin inhibitor heavy chain H3 1.529 4.69 x 10-15 
EN02 Enolase 2 (y, neuronal) 1.520 2.95 x 10-13 
PVALB Parvalbumin 1.477 7.28 x 10-13 
OTX2 Orthodenticle homeobox 2 1.460 3.86 x 10-08 
Log ratio down-regulated 
RPRML Reprimo-like -2.173 5.42 x 10-19 
MAK16 MAK 16 homolog (Saccharomyces cerevisiae) -1.481 3.60 x 10-11 
THAP4 THAP domain-containing 4 -1.081 6.54 x 10-08 
CHRNA3 Cholinergic receptor, nicotinic, a3 -1.071 1.08 x 10-08 
MTOH Metadherin -1.055 1.39 x 10-07 
MAP2 Microtubule-associated protein 2 -0.953 8.11 x 10-06 
MCM6 Minichrom050me maintenance complex component 6 -0.937 1.42 x 10-06 
GST01 GST (0)1 -0.911 3.43 x 10-07 
SFRP1 Secreted frizzled-related protein 1 -0.868 1.16 x 10-05 
ISLR2 Ig superfamily containing leucine-rich repeat 2 -0.830 3.87 x 10-03 
OTX1 Orthodenticle homeobox 1 -0.820 9.15 x 10-05 
A cutoff of log ratio ~10.51 and P:s 0.05 were used to define focus genes in the network analysis. 
Table 3.3 Top genes differentially expressed in saridegib treated PtcC/C tumor 
A cut-off of log ratio ~ 10.51 and p-value ~ 0.05 were used to define focus genes in the network analysis. 
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Forward primer, 5' ..... 3' Reverse primer, 5' ..... 3' 
Exon (each prefixed with M 13 forward) (each prefixed with M 13 reverse) 
AAGCTGGCCCCAGACTTTC CAACAGTTTGAGGCCTGAGC 
2 GCATAAGGCAACCCTTAGCA GCTTGACAACCATGCTCCAT 
3 GCCCTATGAGGTAGGGGCTA AGCCACAAAGGTGGCCTAAA 
4 CACCAGGACATGCACAGCTA GGACACAGGTCGGATTTGAA 
5 AGCATTGCCCTGTTGTGTTC CCAGCACGGTACCGATAGTTC 
6 CTATGCCTTGATGGCTGGAG GAACCTTGGTCATGGCTTTG 
7 AGGCTCTGTCCCAGTT ACCG CCCCTTCTCAGAGGGAGTIG 
8 TGTAGCCACCCTGGACTCAG ACCTGCTCCTGTGCATIGAC 
9 CCATGAGAATCACGCAGTGG GGCTCCTGTGGCTCCTACTT 
10 CTGTGAAGGCCTCAGCTCCT CAGAGAAGAAGGAAGAGAGAGCAA 
11 GCTCCAGGGTGGAA TCTCTC CACTGTCAGGGGGACAAAGA 
12 ACCTGAAGGAGATGCCAAGG CAGACACTTGGCCCACAGAC 
PCR primers were designed with Primer3 and incorporated either M13 forward (5'-TGTAAAACGACGGCCAGT-
3') or M13 reverse (S'-CAGGAAACAGCTATGAC-3') priming sites. 
Table 3.4 Primer used for sequencing 
PCR primers were designed with Primer3 and incorporated either M13 
forward (TGTAAAACGACGGCCAGT) or reverse (CAGGAAACAGCTATGAC) priming sites. 
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CHAPTER 4 
Mid-Size Medicines for the Treatment of Brain Cancer 
Summary 
Our study focused on identifying cysteine knot peptide variants that differentially recognize 
medulloblastoma brain cancer cells. We found that glypican-2, a member of the proteoglycan family, was 
markedly elevated in medulloblastoma cancer cells compared to normal brain cells. Glypicans are 
typically thought to act as co-receptors for other growth factors signaling pathways (e.g., integrin, and 
protein-tyrosine phosphatase) (Sakamoto and Kadomatsu, 2012). Glypican expression is associated with 
a wide variety of cancers including hepatocellular, breast, ovarian, and pancreatic cancer, although the 
particular role of glypican-2 has not been well studied. Previous studies indicate that dimerized midkine 
acts as a pro-oncogenic ligand that activates glypican-2. We hypothesize that monomeric midkine would 
act as a dominant negative-binding to glypican-2 in competition with the dimerized form. Our aim is to 
express only a C-terminal half of midkine that would bind to glypican-2, but would not crosslink the 
receptor and initiate signaling. It is hoped that this could inhibit both full-length midkine and inhibit the 
shared glypican pathway used by a variety of growth factors. If successful, these foundational studies 
would provide the insights into the use of cysteine knot peptide variant libraries and, also, produce novel 
cancer-specific variants that may be used directly to develop cancer therapeutics. In the event that the 
engineered midkine derivative specifically binds to medulloblastoma cells, but does not interfere with 
growth, the peptide could be used to target chemotherapy specifically to medulloblastoma cells. 
Introduction 
Peptide therapeutics and diagnostics 
Cysteine-knots miniproteins, also known as knottins, are small bioactive proteins (20-40 amino 
acids) that are heavily disulfide bonded, conferring structural stability and protease resistance. They are 
commonly found in the venom of poisonous insects and have therefore been designed through evolution 
to be effective as injectable drugs. Knottins possess natural properties that make them attractive for in 
vivo applications. First, their highly cross-linked core structures confer high thermal and proteolytic 
stability. Consequently, knottins have been shown to retain their 3D structure in harsh environments 
(e.g., acid, base, serum), making them potentially suitable for oral drug therapy. Second, knottins have 
the ability to disrupt protein-protein interactions. Unlike small molecules, peptides can be selected for 
broad interfaces with proteins and can block protein interactions. Further, their small size has translated 
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well into desirable pharmacokinetic and biodistribution properties for molecular imaging applications. 
The small size of these knotted proteins can penetrate into solid tumors, perhaps more effectively than 
antibodies. Remarkably, although they are 40 times smaller than an antibody, they possess similar 
amounts of variable region and therefore maintain antibody-like specificity (antibodies generally utilize 
only a small fraction of their Complementarity Determining Regions, with the rest serving as germline 
scaffolding). While knottin peptides can be engineered to match antibody affinity, some knottins appear 
superior to antibodies for crossing the blood brain barrier (BBB) and penetrating into solid tumor tissue. 
The first knottin-based protein that was developed in our lab is a tumor-imaging agent, a 
bioconjugate of chlorotoxin and a near infrared fluorophore, called the Tumor Paint. This imaging agent 
is capable of targeting and illuminating brain tumors, even in the presence of an intact BBB. Therefore, 
the use of a knottin scaffold to generate peptides with drug-like properties is a promising strategy for the 
development of therapeutics for brain tumors. 
Heparan sulfate proteoglycans (HSPGs) 
Heparan sulfate proteoglycans (HSPGs) are composed of a core protein to which a number of 
highly charged heparan sulfate polysaccharide chains (40-300 sugar residues) are covalently linked. The 
basic heparan sulfate structure consists of a repeating disaccharide, constituted by uronic acid and 
hexosamine residues with various degrees of sulfation. HSPGs are ubiquitously expressed in many 
animal cells and are a major component of extracellular environment in brain. Present on the cell surface 
and i~ extracellular membrane (ECM), HSPGs play an important role in a number of biological processes 
based on their ability to bind and regulate activities of a wide range of ligands including cytokines, 
chemokines and growth factors (Kirkpatrick and Selleck, 2007). HSPGs can localize bound signaling 
molecules to their cognate receptors on cell surfaces, or help to form molecular gradients for directional 
cellular activities. In addition, HSPGs are typically thought to act as co-receptors for growth factors 
which bind to their heparan sulfate glycosaminoglycan (GAG) chains. Interaction between fibroblast 
growth factor (FGF) and heparan sulfate chains is a well-studied example. The binding ofFGF2 to its 
receptor, FGFR, causes phosphorylation of tyrosine kinase domain of the receptor and leads to increased 
growth, migration, and differentiation in several cancers. HSPGs play an integral role in FGF2-FGFR 
interaction by localizing FGF2 near the receptor and forming a bridge that stabilizes the ligand-receptor 
complex (Raizen et aI., 2006). 
Since HSPGs can act as co-receptors by facilitating the formation of ligand-receptor complexes 
and effectively altering the required concentration of ligand, it is not surprising that they are expressed in 
the tumor environment. Indeed, glypican expression is associated with a wide variety of cancers 
including hepatocellular, breast, ovarian, and pancreatic cancer and some studies have shown that 
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glypican families (HSPGs that are GPI-linked) are important for efficient angiogenesis and metastasis of 
the cancer (Aikawa et aI., 2008). 
Glypicans 
Glypicans are family ofHSPGs that are linked to the external surface of the plasma membrane 
via glycosylphosphatidylinositol (GPI) anchor (Figure 4.1). Glypicans have negatively charged heparan 
sulfate GAG chains (Galisteo et aI., 2006) that are covalently linked to a core protein core (40-70kDa). 
Heparan sulfate GAG chains are responsible for biological functions ofHSPGs and the core proteins have 
evolved to maximize their efficiency in these functions. 
Glypicans comprise a family of six distinct genes in mammals (Galisteo et aI., 2006) (Table 4.1). 
Glypicans can be divided into two broad subfamilies: glypican-l, -2, -4, -6 and glypicans-3, -5, with 
approximately 25% amino acid identity between groups. However, the fact that GAG chain moieties 
mediate much of the function of glypicans, a likelihood of functional redundancy is particularly high. All 
glypicans are highly expressed during embryonic development. Interestingly, their expression levels vary 
in a tissue-specific manner. Glypican-l is a major proteoglycan in the developing and adult brain, but it is 
also expressed in the kidneys, perichondrium, and several other tissues (David et aI., 1990). Glypican-2 
(cereberoglycan) expression, in contrast, is expressed exclusively in the developing brain (Stipp et aI., 
1994). Glypican-2 expression peaks as neurons differentiate and migrate to their appropriate locations 
and extend neurites, and then the expression is turned off. Glypican-3 is highly expressed in the 
developing intestine and in mesoderm-derived tissues (Pellegrini et aI., 1998), whereas glypican-4 shows 
a predominant expression in blood vessels, kidney, brain, and adrenal cortex (Watanabe et aI., 1995). 
Glypican-5 shows a developmentally regulated expression in kidney, limb, and brain (Saunders et aI., 
1997), with brain expressions that persist into the adult. Glypican-6 shows predominant expressions in 
mesenchymal tissues during development. Consistent with a proposed role in development, the 
expression patterns of these glypicans often coincide with those of growth factors (e.g. Wnt, Shh, BMP, 
TGF~, and EGF, and FGF), and their receptors (Yayon et aI., 1991). 
Since glypicans are expressed predominantly during development, defects in glypican expression 
generally produce subtle and tissue-restricted defects (Perrimon and Bernfield, 2000). Most likely this 
reflects a relatively large number of HSPGs (six glypicans), and a likelihood of functional redundancy. 
Glypican-l and -3 null mutant mice were viable and fertile. No mutants have been reported for glypican-
2, -4, -6. Glypican-l knock-out mice showed significant reduction in brain size (22% reduction compared 
to the wild-type littermates), with only subtle mispatterning in anterior cerebellum (Jen et aI., 2009). 
Heparan sulfate-based treatment strategies 
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The involvement of glypican genes in cancers has raised the question whether they can be targets 
of molecular therapies. Given the ability of heparan sulfate chains to bind to a variety of regulatory 
proteins, the potential treatments of malignancy involving HSPGs are aimed at targeting such 
interactions. 
One main target for heparan sulfate-based therapy is inhibition of heparanase activity. 
Heparanase is an endo-~-glucuronidase capable of cleaving the heparan sulfate side chains of HSPGs 
(Afratis et aI., 2012). Upregulation ofheparanase has been documented in human cancer of various 
origins, including colon, gastric, liver, and pancreas (Hermano et aI., 2012). In many cases, heparanase 
induction correlated with increased tumor metastasis, angiogenesis, and poor patient outcome (Vlodavsky 
and Friedmann, 2001; Ilan et aI., 2006), thus suggesting heparanase as an attractive therapeutic target. A 
variety of inhibitory compounds have been developed, including heparin, heparin-mimicking compounds, 
PI-88 (phosphomannopentaose sulfate), and low-molecular-weight heparin (LMWH) - a series of heparin 
fragments that share many of heparin's activities. Current clinical trials using a heparan sulfate mimic 
and heparin-like polyanionic compounds that inhibit heparanase activity have produced promising results 
in cancer patients (Klerk et aI., 2005; Rickles, 2006). For example, PI-88 is currently being evaluated in 
multiple phase IIIIII trials for recurrent hepatocellular carcinoma, prostate cancer, metastatic melanoma, 
and multiple myeloma (Liu et aI., 2009). This inhibitor prevents angiogenesis and tumor growth by 
blocking specific interactions ofFGF and VEGF with their receptors and heparan sulfate chains (Ferro et 
aI., 2007). 
Other possible heparan sulfate-dependent treatments for cancer therapy involve proteins or 
peptides with positively charged amino acid residues that act as competitive inhibitors of growth factor 
binding to heparan sulfate chains, thereby attenuating down-stream receptor signaling activation. An 
example is suramine, which has the ability to bind to heparin-binding sites of proteins (Marchetti et aI., 
2003) and is undergoing phase III clinical trial for advanced stage breast cancer patients. 
Since heparan sulfate chains are Ubiquitous in our body, the clinical application of targeting 
heparan sulfate chains still requires a better understanding of the specificity involved in HS-protein 
interactions. 
Midkine (MK) 
Midkine (MK) is a heparin-binding neuroregulatory factor that participates in neuronal cell 
migration and neurite outgrowth (Muramatsu, 2002). Previously, it was reported that midkine binds to 
oversulfated structure in heparan sulfate in glypican-2 (Kurosawa et aI., 2001). MK is strongly expressed 
during the embryogenesis, but in adults it is only expressed in damaged tissues and involved in the 
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reparative process. MK is also expressed in a variety of malignant tumors and promotes their growth and 
invasion. 
MK is a highly basic, non-glycosylated polypeptide that contains five intrachain disulfide bonds. 
MK has a molecular weight of about 13kDa (Figure 4.2A). MK is composed of two domains that are 
linked by disulfide linkage (Fabri et aI., 1993). Initial structural and functional studies indicated that the 
C-terminal half of MK contains the main heparin-binding sites and this is responsible for the main 
mechanism of action. C-terminus domain has two clusters of basic amino acids: Cluster-l (K79, R81, 
and K102) and Cluster-2 (K86, K87, and R89) (Akhter et aI., 1998; Iwasaki et aI., 1997) (Figure 4.2B). 
MK forms dimers via spontaneous association and when it does, Cluster 2 in the C-terminal domains 
form fused heparin-binding site at the dimer interface (Figure 4.2C). This fused heparin-binding sites on 
MK fit the sulfate group clusters on heparin (Iwasaki et aI., 1997). MK dimer has shown to be the active 
form and dimerization ofMK allows stronger heparin-binding activity. 
Molecular Dynamics (MD) 
Proteins are not static but dynamic. The backbone and side chains of proteins are in constant 
motion due to thermal motion or kinetic energy of the atoms. Although X-ray crystallography gives 
detailed structural information, it is only a time-averaged snapshot of the protein structure with no kinetic 
information. On the other hand, nuclear magnetic resonance (NMR) can detect motion of individual 
atoms within protein, but give limited structural information. No single experiment or combination of 
experiments can provide an all-inclusive view of the dynamic behavior of all atoms in a protein. 
Computational studies, however, can provide complementary tool to help study structure and dynamics of 
the protein. A method that has had a particularly large impact is molecular dynamics (MD). MD is a 
theoretical physics technique for examining the complex molecular motions and conformational changes 
in protein, which is often important for understanding their function (Doniach and Eastman, 1999). MD 
simulation integrates classical Newton's equations of motions and for all atoms in the molecular systems 
over time. In order to describe the energy of a particular protein system, it is necessary to 1) get a starting 
configuration of the atoms in the system, 2) set configuration in motions, and 3) calculate a new 
configuration based on such motions. The equations of motions are of sufficient complexity that the 
integration is done over a large number of very small discrete time-steps (less than 2fs). At each time 
step, the potential energy of a system in terms of the geometries of atomic centers is calculated. All atom 
molecular mechanics force fields due to intramolecular interactions (e.g., bond lengths, bond angles, and 
dihedral/torsion angles) and non-bonded energies (e.g. , Van der Waals and electrostatic interactions) are 
considered. In the end, MD simulations provide the ultimate detail concerning individual particle motions 
as a function of time. 
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In this study, we aimed to engineer the fragment of natural ligand of glypican-2 and 
computationally designed mutant variants that could potentially act as competitive inhibitors. 
Furthermore, we employed MD on various these peptide variants to investigate their stability. We 
investigate how the mutations introduced impact dimerization and conformations of the heparain binding 
clusters in MKC. The mutant version ofMKC we present even have a physiological relevance to cell 
studies. 
Results 
Overexpression of Glypican-2 in different types of brain cancers 
We analyzed gene expression profiles in 12 pediatric medulloblastoma patients. Among 48,702 
probe sets used in the Illumina beadchip, 1318 probe sets had greater than log2Fc=2 and statistically 
significant difference (P <0.005) between all tumors and normal adult brain. Candidate targets were 
narrowed down to 250 probe sets based upon their surface expression. These include genes known to be 
relevant in oncogenesis such as cell proliferation, apoptosis, development, angiogenesis, invasion and 
metastasis. We further narrowed down the gene list to genes that have limited expression in normal 
tissues (e.g., kidney, liver, brain) and that have known peptide ligands. Among the 250 over-expressed 
genes, we chose to study glypican-2 due to its high level of expression in medulloblastoma compared to 
normal brain (average: 4.64 fold) and its limited expression in normal tissues other than brain. 
Overexpression of Glypican-2 mRNA was also observed in other types of brain cancers including 
glioblastoma, PNET, and astrocytoma (Figure 4.3A). To validate our results at the cellular level, 
immunohistochemistry was performed on the four medulloblastoma samples (three orthotopic xenograft 
and one genetically engineered mouse models). As shown in Figure 4.3B, there were marked 
overexpression of glypican-2 only in medulloblastoma cancer cells and not in normal brain, although the 
level varied among samples. 
Designing mutant versions of C-terminal domain of MK (MKC) 
In order to design competitive inhibitors of hepar an sulfate chain of glypican-2 that prevent cross-
linking the signaling complex, we focused on designing variants involving the C-terminal half of MK 
(from now on denoted as MKC). First, the dimer form ofMKC was manually created using Chimera by 
aligning two MKC monomers (from now on, we denote each monomer by MKC-A and MKC-B) based 
on the proposed dimer model (Iwasaki et aI., 1997). When designing new protein, we used computational 
methods to assay theoretical point mutations and rotamer optimization for increased stability and function 
of the protein. Using Foldit software, the sequence and conformation of a protein were optimized to find 
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low-energy sequence-structure pairs. Although the mutations were not explicitly modeled in the presence 
of the substrate or heparan sulfate, we hypothesized that some of the proteins in the designed library 
would prevent formation of co-receptor while still allowing heparan sulfate to bind. 
The disulfide-rich knottin scaffold is considered as a useful stabilizing framework. Therefore, we 
kept two disulfide bonds (Cysl-Cys33 and Cysll-Cys43) intact within MKC in the process of 
introducing mutations. A summary of each mutant is given in Table 4.2. In Mutant 1 , alllysines were 
changed to arginines. Mutant! was generated based on our previous experimental knowledge that 
multiple lysine residues can lead to multi-labeled fluorescence molecule rather than a single-labeled 
peptide that is preferable for drug development and manufacturing. For Mutant2, negatively charged 
(e.g., Aspartate) and positively charged (e.g., Arginine) residues were introduced to create stabilizing salt-
bridges. For Mutant3, mutations were introduced along linker regions (between two monomers) for 
stronger dimerization. For Mutant4, mutations were only made on the surface opposite to the heparin 
binding sites. 
Potential energies and number ofR-bonds were calculated using software Chimera and the results 
are reported in Table 4.2. Mutant! had no change in total number ofR-bonds; however, substitution of 
lysine to arginine significantly decreased the potential energy (-10659.37). In case of Mutant 2 and 
Mutant3, there was no significant change in the number ofR-bonds but both were more stable than WT. 
Mutant4 had the lowest potential energy (-11188.03). 
Dynamics of MKC WT and mutants 
Backbone Motion 
Four engineered MKC variants were then tested for stability with respect to fold and shape of 
heparin binding clusters. First, the constructed models were fitted to minimize steric clashes 
using Chimera. Minimized structures are shown in Figure 4.5. The original secondary structure of 
MKC monomer has three ~-sheets. Rowever, after minimization step in dimer form, MKC-A retained 
two ~-sheets and MKC-B lost all three ~- sheets secondary structure. 
To elucidate the dynamics ofMKC variants, we performed MD simulations ofMKC structures 
with four different mutants at body temperature totaling l5ns of simulation time. The convergence and 
the stability of the MD trajectories were quantified by Ca RMSD, the measure of the deviation of the 
protein from the initial NMR structure. At body temperature (37°C), Mutant2 had the lowest core Ca 
RMSD to the starting structure (5.05 ± 0.0835 A) over the step 1800-2000 of stimulation (Figure 4.6A). 
Continuous increase in Ca RMSD in WT, Mutantl, and Mutant4 indicate sustained changes in structure 
(Figure 4.6B). Not only did the core Ca RMSD for Mutant! increased over time, but also did its standard 
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deviation, indicating higher structural heterogeneity. On the other hand, Ca RMSD values for Mutant3 
and Mutant4 were stabilized after 1500 ps of simulation. 
The Ca RMSF (measure of the deviation between the position of certain residue and initial 
reference position) was calculated for the core residues over all simulations at 37°C (Figure 4.6C). All 
four mutants had lower fluctuations about the mean structure than WT. Residues in Mutant3 had the 
lowest fluctuations, indicative of a rigid structure. As expected, the most rigid regions were within the ~­
sheets (near residues 4-5; 20-24; 37-39). 
Secondary structure Analysis 
The dictionary of secondary structure of proteins (dssp) algorithm was used to determine protein 
secondary structure by looking for repeating main-chain hydrogen bonding patterns (Figure 4.7). A 
hydrogen bond was assigned if the distance between donor and acceptor atoms was less than 4.0 A. Dssp 
module detected alpha-bridges (green), 3/10 helix (pink), beta sheets (red) as well as their corresponding 
bridges. In MD simulation, secondary structures were lost in almost all simulations, except for MKC-A 
ofMutantl and Mutant4. With mutant 4, nine additional H-bonds were formed, resulting in the 
stabilization of the native B-sheet. In contrast, mutant2 showed the loss of five hydrogen bonds and 
disrupted the native B-sheet. The numbers of hydrogen bonds for each mutant were shown in Table 4.2. 
Core contacts analysis 
Two non-bonded residues are considered to be in contact when they are spatially neighboring. If 
a contact is the same.as it presents in the native structure (starting structure), it is called a native contact, 
otherwise a non-native contact. Considering the protein dynamics microscopically, residues with more 
native contacts are energetically more favorable. Native contacts are more frequently formed in properly 
folded protein, whereas non-native contacts are more frequently formed in the misfolded protein. 
Native and non-native contacts in the 37 DC simulations of WT and four mutants are plotted in 
Figure 4.8, with native contacts in grey and non-native in white. The average numbers of contacts per 
frame in simulations are organized by whether they occurred between atoms in the main chain (mc) or 
side chain (sc). Mutant2 gained contacts especially native side chain contacts. However, Mutantl gained 
more non-native contacts and Mutant3 and Mutant4 had no significant change. 
Table 4.3 shows the percentage of charged residues as well as salt bridges formed in each mutant. 
For Mutant 1 , there was no change in number of charged residues. Lysine to arginine mutation allowed 
the formation of Arg2-Glu35 and Arg20-Glu6 native salt bridges (Lys2-Glu35 and Arg20-Glu6 were 
non-native contacts in WT). In case ofMutant2, 34.88% of residues were charged and five out of seven 
salt bridges detected were native contacts. All the salt bridges found in Mutant3 were non-native, which 
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may deter the native salt bridge from forming. Mutant4 had the highest percentage of charged residues 
(41.86%; 18 out of 43 residues) and thirteen salt bridges were detected. However, more than half were 
non-native contacts. 
Biochemical characteristics of WT and Mutantl MKC 
First, we expressed WT MKC in E.Coli expression system and Daedalus expression system in 
mammalian 293T cells (Bandaranayake et aI., 2011) (Figure 4.9). Expressed proteins were purified using 
size exclusion chromatography (SEC) and ran on SDS-PAGE gel. MKC expressed in E.Coli showed 
some extent ofmisfolding, indicated by smeared multiple bands in SDS-PAGE gel. (Figure 4.10B). 
MKC expressed in the mammalian system was properly folded, suggested by tight single band. The 
ability ofE.Coli and mammalian MKCs to bind to heparan sulfate chain was examined using heparin-
binding column chromatography (Figure 4.10A). Mammalian MKC eluted as a narrow peak centered at 
0.86M NaC!, whereas E.Coli MKC came off at 0.8M NaC!. The result indicated that mammalian MKC 
has higher binding affinity for heparin than E.Coli MKC. 
Since MKC proteins failed to fold correctly in E.Coli, we decided to carry all MKC protein 
expression in Daedelus mammalian system. WT MKC was eluted as a single, monodispersed peak from 
a SEC, which is an indication of structural homogeneity of the sample (Figure 4.11A). By SDS-PAGE, 
TEV cleaved fusion protein yielded a single band. In the case of Mutant 1 MKC, two monodisperse peaks 
were detected on SEC, suggesting existence of both monomer and dimer (Figure 4.11B). The earlier 
fraction contained primarily dimer, whereas later fractions contained monomers. These two peak 
fractions were ran in SDS-PAGE gel separately and difference in size confirmed the presence of dimer. 
Replacement of all lysine residues to arginine increased dimerization of MKC. 
Discussion 
Glypican-2 is a rational target for the treatment of brain cancers because it is predominantly 
expressed in brain tumors compared to normal brain tissue, implying specificity. In addition, it 
potentially regulates multiple pathways involved in carginogensis, implying a broad spectrum of activity. 
In this study, we took the fragment of natural ligand ofglypican-2 and computationally and 
experimentally explored the dynamical behaviors of WT and mutant MKC. 
Computational structural analysis indicated that all four MKC mutants were more stable than the 
WT. Previously, it has been shown that addition of salt bridges on the protein surface results in increased 
thermostability. Salt bridges are special form of hydrogen bonds, composed of negative charges from 
Asp, Glu, Tyr, Cys and the C-terminal carboxylate group, and of positive charges from His, Lys, Arg and 
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the N-terminal amino group. In designing Mutant2, six residues were mutated to charged polar residues: 
Y3R, T15R, VI9E, K25D, Y29D, A31K. (Four additional mutations: K2S, DI2G, T23A, N30S). Many 
non-native salt bridges formed in the simulations may keep residues involved in native contacts from 
finding each other. In Mutant2, four out of six mutated polar residues spent time making salt bridges with 
other charged residues. It is important to note that WT had more contacts on average than Mutant2, yet 
Mutant2 made greater number of native contacts. All these data indicates that there were no large 
structural changes in Mutant2. 
Mutant3 was more rigid in our simulation than any other mutants. In particular, there was less 
fluctuation in the backbone as observed by lower Ca RMSD and Ca RMSF in Mutant3 relative to WT or 
other mutants at 37°C (Figure 4.4). Mutant3 only formed non-native forms of salt bridges, which may be 
a possible explanation for complete disappearance of secondary structure in MKC-A during MD 
simulation (Figure 4.4). 
In case ofMutant4, hydrophobic surface residues on WT MKC were mutated to polar residues: 
K2S, Y3E, AIOR, T15R, T17A, V19E, T23A, T36R, I37T, V39D, T40K, P42D. Since alanine and 
threonine side chains are generally non-reactive and rarely directly involved in protein function, we 
mutated those residues to arginine or lysine, introducing positive charges that could potentially be 
involved in forming salt-bridges. The additional H-bonds in Mutant4 helped stabilize the mutant and 
retain secondary structure. 
In summary, we have investigated the dynamics of WT MKC and its engineered stabilized 
variants. We computationally designed MKC mutants that are more stable as a dimer and validated our 
MD simulation by expressing WT and Mutant! MKC in a Daedalus mammalian system. Biochemical 
analysis (e.g., Size exclusion column, SDS-PAGE) of Mutant! MKC showed great improvement in its 
stability as a dimer compared to WT MKC. According to MD simulation, Mutant2, 3, 4 have more 
favorable characteristics than Mutant} (e.g., lower RMSDIF, greater native contact). Our goal is not only 
to design a more stable MKC dimer, but also a peptide that can inhibit the shared glypican pathway used 
by a variety of growth factors. Other biochemical properties (e.g., affinity toward heparan sulfate chain), 
tumor-homing effect (e.g., ability to cross blood-brain barrier, specificity toward tumor), and therapeutic 
implications (e.g., ability to kill cells) of computationally designed MKC mutants will need to be further 
investigated. 
Materials and Methods 
Expression Analysis 
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Microarray data from Zhao et aI.(Zhao et aI., 2012), Li et aI. (Li et aI., 2009) and Liu et aI. (Liu et aI., 
2011) were obtained from Gene Expression Omnibus (accession no. GSE 28192, GSE14296, 
GSE21354). GSE28192 consists of normal fetal brain (n=4), adult cerebellum (n =5), and childhood 
cerebellum (n =1), and primary medulloblastoma tumors (n=12). GSE 14296 consists of normal fetal 
brain (n=7), normal adult brain (n=7), and primitive neuroectodermal tumors (n=55). GSE21354 consists 
of normal brain tissue sample (n=3) and grade II gliomas (n=14). GE02R was used to perform R-based 
analysis ofGEO data to identify differential gene expression (http://www.ncbLnlm.nih.gov/geo/ge02r) 
Immunohistochemistry 
Tissues were cut into 4-llm sections and immunostained with biotinylated primary antibody 
against glypican-2 (R&D Systems). Secondary antibody were applied according to Vectastain Elite 
avidinbiotin complex method instructions (Vector Laboratories), and detection was carried out with 3,3'-
diaminobenzidine reagent (Vector Laboratories). Sections were visualized with Nikon E800 microscope. 
Structure Preparation 
The starting structure of wild-type (WT) human MK for MD simulations was modeled based on a 
NMR structure ofC-terminal domain of human MK (MKC; PDB code 1MKC) (Iwasaki et aI., 1997), 
which contains residues 84-126. The MKC structure were renumbered to align with numbering used in 
ilmm, and they are discussed using residues 1-43 instead of 84-126 to avoid confusion. The dimer form 
of MKC was manually created using Chimera software (www.cgl.ucsf.edu/chimera) by aligning two 
MKC monomers (MKC-A and MKC-B) based on proposed dimer model (Iwasaki et aI., 1997). 
Automatic moves from Foldit software - combinatorial side-chain rotamer packing ('shake'), gradient-
based minimization ('wiggle'), amino acid redesigning ('mutate') - are used to design new proteins. 
(Summary in Figure 4.4) 
MD Simulation Protocol 
All simulations were performed using MD software, in lucem molecular mechanics (ilmm). The 
simulations began from the crystal structure of mid kine C-terminal domain (PDB ID: 1MKC). 
Minimization was performed using the force field for 1000 steps of steepest decent minimization. Each 
system was prepared as per our standard protocols (Beck and Daggett, 2004) using a water box that 
extended loA past the edge of the protein on all sides filled with water molecules. The final water 
density of the system was adjusted to the experimentally measured density of 0.993 g/mL. All simulations 
of WT and mutant MDK proteins were performed at 310 K for 15 ns. Simulations included all hydrogen 
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atoms and used using 1.8 A as the radius of exclusion for waters around solute. Two to three independent 
MD simulations were performed for WT and for each mutant. 
Simulation Analysis 
The root-mean-square deviation of the Ca atoms (Ca RMSD) to the simulation starting WT and 
mutants structure was calculated for the core residues of all proteins. The RMSD was also calculated 
between all structures and then averaged to give average core Ca RMSD. The Ca root-mean-square 
fluctuation (Ca RMSF) about the mean structure over time was also calculated for the core residues. The 
mean structure for each protein was calculated by averaging the coordinates for each Ca atom across 
simulation time. 
Contacts were counted and classified in several different ways. First, contacts were defined as 
native or non-native based on whether they occurred in the starting structure. They were also classified 
based on whether the contacting atoms were in the main chain (N, Ca, C, 0) or side chain. Atoms were 
considered in contact for carbons that were ::s5.4 A apart or non-carbon atoms that were :s4.6 A apart. 
Hydrogen atoms were not considered, nor were interactions within a residue or between neighboring 
residues. Residues were considered in contact if they contained at least one contacting atom pair. 
Furthermore, the secondary structures of protein were assessed using the Define Secondary Structure of 
Proteins (DSSP) program. 
Expression of WT and Mutant] MKC in mammalian cells 
Mutant libraries were created using an oligonucleotide assembly approach. The assembly 
reactions were amplified with primers containing XhoIlBamHI sites and the purified PCR products were 
cloned into the Daedalus vector pCVL-sUCOE-SFFV-IRES-GFP (Bandaranayake et aI., 2011). The 
resulting lentivirallibrary was used to transduce HEK 293 cells to create a polyclonal population of cells 
secreting variants. Each library consists of either the parental scaffold alone, containing an N-terminal 
secretion signal and a C-terminal STREPII tag, or the parental scaffold fused to a secretion partner 
(siderocalin). The secreted peptide fusions were harvested from the culture supernatants using size-
exclusion chromatography (SEC) on a Superdex 75 column (GE Healthsciences). Proteins were detected 
by Coomassie blue staining of sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE). 
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Figure 4.1 A proposed model of Glypican-2 and mid kine action 
Core protein of glypican-2 is decorated with long, charged polysaccharide heparin sulfate chains. 
Midkine, which acts as a dimer, binds to heparin sulfate chains and promotes the formation of the 
receptor complexes and regulates cell proliferation, differentiation and patterning. 
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Figure 4.2 Midkine sequence and structure 
View 2 
(A) Primary structure of human midkine. Key amino acids involved in heparin binding (cyan, Cluster-1; 
magenta, Cluster-2). Lines show the position of disulfide linkages. (B) Two heparin-binding sites in the 
C-terminus domain are encircled. On the surface, red represents negatively charged elements, white 
represents neutral elements, and blue represents positively charged elements. (C) The model for midkine 
Codomain (62-104) head-to-head dimer complex is shown. Cluster-2s in the C-terminus domains form 
fused heparin-binding site at the dimer interface. This fused heparin-binding sites fit to negatively 
charged clusters of heparin. 
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Figure 4.3 Expression of Glypican-2 in brain cancers 
(A) mRNA expression of glypican-2 was calculated in five different types of brain cancer. Three different 
GEO datasets were used to analyze level of glypican-2 expression. (Expression level was normalized to 
normal adult brain; error bars = SEM). (B) The expression of glypican-2 in medulloblastoma cancer cells. 
Immunohistochemistry demonstrated that glypican-2 was highly expressed in human medulloblastoma 
orthotopic xenografts and genetically engineered medulloblastoma mouse but absent in adjacent non-
tumorous normal tissues. (Cx: normal brain; Cb: normal cerebellum) 
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Figure 4.4 Designing MKC peptide variants 
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NMR structure of C-terminus domain of mid kine was obtained from Protein Data Bank (PDB) and dimer 
form was generated. Using Foldit, the sequence and conformation of a protein were optimized to find 
low-energy sequence-structure pairs. 
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Secondary Structure Minimized structure view 1 Minimized structure view 2 
WT 
Mutantl 
Mutant2 
Mutant3 
Mutant4 
Figure 4.5 3D structures of WT and four MKC mutant dimers 
(Left column) Secondary structure of minimized WT and mutant MDK dimers are shown. Disulfide 
bonds are colored in yellow and H-bonds are colored in cyan. (Middle and right column) All residues 
within 4 A of mutation sites are colored in cyan. Mutation sites are shown in magenta. 
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Figure 4.6 Core Ca RMSDIF in MD simulations 
(A) The average Cn RMSD of the core residues over the last 20ns of each of the two to three independent 
simulations in plotted for WT and mutant MKC with the standard deviation denoted by error bars. (B) 
The core Cn RMSD was averaged at each time point over the independent simulations and is plotted over 
time for WT and mutant MKC. (C) The core Cn RMSF is plotted for each residue in WT and mutant 
MKC. 
67 
Secondary Structure 
WT 
Mutantl 
Mutant2 
Mutant3 
Mutant4 
:;: 
:' 
I 
~" ,,-
:l 
:l 
~o 
... -
I 
" a 
'I 
" 
-
§~ 
... 
:; 
:} 
:! 
~ 
I 
F 
.. 
.. 
:l 
~ 
;! 
... 
~ 
MKC-A 
:: 
--
.. -; 
~ 
~ 
- i 
..... 
' 0 ,. 
'" ResimJe N\lmber 
I 
--
--
--
.. ! .. . 
:: 
I. ... 
_N...-
~ 
;';" -
!!! 
" 
". 
'" ReSIdue N~ber 
I. 
;-
-
. ,:,:, 
.. 
. :::: 
. :. 
.= 
. :::; 
. ~ 
.. 
- i ---:.:. 
. : 
.:... 
.:::: 
.:. 
. ::;: 
-=: 
-::,. 
~ 
.. 
--
.'-
. ::: 
. ;.. 
. :::: 
. ::. 
. ::; 
. ::: 
. ::. 
.. 
-. 
-!! 
.::: 
--
.::: 
.:. 
. ::;: 
.= 
.::, 
- ! 
.. 
--
-.!:. 
.::: 
.-
.:::: 
. ::. 
. ::: 
.::: 
. :::.. 
Figure 4.7 Backbone mobility in WT, and four mutant MKC dimers 
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the least mobile among all. (Middle and right column) MD dssp analysis of WT and mutant dimers. 
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Figure 4.8 Main chain and side chain contact analysis during MD simulation 
Total number of contacts for the core residues of WT and four mutant MKC dimers are plotted. The sold 
portion of the bar indicates native contacts and white portion indicates non-native contacts. (error bars = 
s.d over time). Contacts are classified as main chain- main chain (mc-ms), main chain-side chain (mc-sc), 
side chain-side chain (sc-sc), and total. 
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Figure 4.9 Expressing knottin proteins using Daedalus platform 
Peptide 
Up to 100mg/l 
(A) Daedalus platform is based on the use oflentiviral vectors that contains a minimized UCOE element, 
which allows for the high level expression of a particular gene. Siderocalin is used as a fusion partner to 
enable recovery of secreted free knottin peptide in the media. (B) Daedalus lentiviral vector is used to 
transduce HEK 293 cells. The secreted peptides are harvested from the culture supernatants. Treatment 
with TEV protease cuts and release knottin protein of interest from the fusion partner and naked peptides 
are purified in a single size exclusion step. 
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Figure 4.10 Biochemical characteristics of E.Coli and Mammalian WT MKC 
30.00 
30.00 
(A) Heparin affinity column ofE.Coli and mammalian MKC. Binding of the E.Coli and mammalian 
MKC WT proteins was assayed by heparin affinity chromatography. Proteins were applied to a heparin 
column, and after extensive washing, bound proteins were eluted using a linear salt gradient (O.O-1.0M 
NaCl). Mammalian MKC showed stronger binding affinity toward heparin. (2) SDS-PAGE revealed that 
Mammalian MKC was properly folded, but E.Coli MKC was not. (NR: non-reducing condition, R: 
reducing condition) 
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Figure 4.11 Biochemical characteristics of WT and Mot.antl mammalian MKC 
(A) Size Exclusion Column analysis (SEC) and SDS-PAGE gel ofWT MKC released from iderocalin 
after TEY cleavage reaction. On SEC WT MKC eluted as a single, monodisperse peak, which is an 
indication of structural homogeneity of the sample. By SDS-PAGE, TEY cleaved protein yielded a single 
band. (B) SEC analysis showed both dimer and monomer forms ofMutantl mammaJian MKC. SDS-
PAGE analysis of these two SEC peaks contilmed the presence of dimers and monomers. (NR: non-
reducing condition R: reducing condition) 
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Name Original Expression in Embryo Expression in Adult 
Designation 
Glypican-l Bone, bone marrow, muscle epidermis, Most tissues 
kidney 
Glypican-2 Cerebroglycan Nervous system Not detected 
Glypican-3 OCI-5 Most tissues Ovary, mammary gland, lung, kidney 
Glypican-4 K-glypican Brain, lung, lung Most tissues 
Glypican-5 Brain, lung, liver, kidney, limb Brain 
Glypican-6 Many tissues, including liver and kidney Many tissues including ovary, kidney, 
liver, and intestine 
Table 4.1 Glypican family during embryogenesis and in adult tissues 
(Adapted from Fico et aI. , 2007) 
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Description Sequence Potential H bonds 
Energy found 
WT CKYKFENWGACDGGTGTKVRQGTLKKARYNAQC -2750.62 58 
QETIRVTKPC 
Mutant 1 Lys to Arg CRYRFENWGACDGGTGTRVRQGTLRRARYNAQCQ -10659.37 58 
ETIRVTRPC 
Mutant 2 Introduction of more negatively CSRKFENWGACGGGRGTKERQGALDKARDSKQCQ -8041.72 53 
charged (e.g., Aspartate) or ETIRVTKPC 
positively charged (e.g., 
Arginine) to create stabilizing H 
bonds 
Mutant 3 Mutation in dimer linker regions CKYKFEN WRACDGGTGTK V RQGTLKNSGYNKECQ -6724.50 59 
ETIRVTKPC 
Mutant 4 Mutation on the opposite side of CSEKFENWGRCDGGRGAKERQGALKKARYNAQC -11188.Q3 67 
heparin binding regions QERTRDKKDC 
Table 4.2 Detailed description of WT and four MKC mutants 
The amino acid sequences, description of mutation, potential energy, and number ofR-bonds ofWT and 
four MKC proteins. Any residue that is different from WT is marked red. 
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Basic residues Acidic residues % of basic and acidic residues Salt brid2e formed 
WT 3 Arg, 6 Lys 2 Glu, 1 Asp 27.9% (12 of 43 residues) **Lys2-Glu35 nn, 
**Lys4-Glu6 nn, 
Lysl8-Glu6 n, 
Lysl8-Aspl2 nn, 
**Arg20-Glu6 nn, 
Mutantl 9 Arg, 0 Lys 2 Glu, 1 Asp 27.9% (12 of 43 residues) Arg2-Glu35 n , 
Arg4-Glu6 nn, 
*ArgI8-Glu6 nn, 
ArgI8-Asp12 n, 
**Arg20-Glu6 n, 
Arg38-Glu35 nn, 
Mutant2 5 Arg, 5 Lys 3 Glu, 2 Asp 34.88% (15 of 43 residues) * * Arg3-Asp25 n, 
**Lys4-Glu6 nn, 
*ArgI5-Glu6 n, 
Arg15-Glu80 n, 
Lysl8-Glu6 nn, 
* * Arg20-Glu6 both n, nn, 
Arg38-Glul9 both n, nn, 
Arg38-Glu35 nn. 
Mutant3 3 Arg, 6 Lys 3 Glu, 1 Asp 30.23% (13 of 43 residues) Lys4-Glu35 nn, 
Arg9-Glu6 nn, 
Lysl8-Glu6 nn, 
**Arg20-Glu6 nn, 
* Arg 18-Aso 12 both n,nn, 
Mutant4 6 Arg, 6 Lys 4 Glu, 2 Asp 41.86% (18 of 43 residues) ArglO-Asp42 nn, 
**ArgI5-Glu6 n, 
** Argl5-Asp 12 n, 
**ArgI5-GluI9 n, 
Lysl8-Glu67 nn, 
Arg20-Asp39 n, 
**Lys25-Glu3 nn, 
Arg28-Glu3 nn, 
Arg38-Glul9 nn, 
** Arg38-Lys40 n, 
**Lys40-GluI9 nn, 
Lys41-Glul9 nn, 
**Lvs41-Aso39 n 
Table 4.3 Analysis of charged residues and salt bridges formed in WT and mutant MKC 
Green: contacts new in mutants; n:native contact; nn: non-native contact; *: high number of contact; **: 
greater than 95% contact, *: greater than 75% contact 
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CHAPTERS 
Conclusion and Future Directions 
Tumor imaging studies 
In the current clinical practice, the intraoperative assessment of the tumor-free margin is 
dependent on visual appearance and palpation of the tumor. NIRF Intraoperative optical imaging has the 
potential of closing the gap between radiology and surgery by providing real-time visualization of the 
tumor. However, there remain considerable challenges bringing NIRF nanoprobe technology to clinical 
practice. First, stability and dispensability of nanoprobe in physiological environments and biochemical 
properties ofnanoprobe might produce unexpected result in vivo. Therefore the pharmacokinetics and 
toxicity of the nanoprobe should be investigated in parallel with their tumor-imaging potential and 
unfavorable biodistribution such as nonspecific accumulation in reticuloendothelial system (RES) needs 
to be resolved. Second, further innovations are necessary to generate NIRF nanoprobe with high quantum 
yield and greater tissue penetration. Currently, indocyanine green (ICG) is the only fluorophore approved 
by the Food and Drug Administration (FDA). Further development and FDA approval of other organic 
fluorophores is essential. Third, parallel development of intraoperative surgical microscope, CCA 
cameras, or endoscopes is required. Existing imaging systems such as surgical microscopes (Zeiss, 
Olympus) and SPY imaging system daVinci Robots (Intuitive Surgical Inc.) are capable of imaging ICG 
in real time. Next generation device will improve on imaging in ambient light condition, higher 
resolution, and subtraction of background signal. Further research is in absolute need to develop more 
sensitive NIR camera system and to correct the measured fluorescence signal for scattering and 
absorption. Although the practical clinical application ofNIRF nanoparobes has many challenges to be 
overcome, continued collaborations among the interdisciplinary research teams will speed up the 
translation process. The NIRF nanoprobe for real-time imaging-guided surgery holds promising 
possibilities for clinical use in the years to come. 
Shh-targeted therapy in medulloblastoma studies 
Human tumors have great genetic diversity, as revealed by gene-expression profiling. One of the 
major challenges in the use of Smo inhibitors for treating medulloblastoma is identification of patients 
who are capable of responding. Although genetic testing can reveal the presence ofPtchl mutations, this 
could only account for a subset of patients (Only 30% of medulloblastoma patients have activated Shh 
pathway and less than 50% of those patients have Path 1 mutations). In addition, the mutation status of 
Smo as well as genes acting downstream of Smo needs to be evaluated. Clearly, improved understanding 
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of the mechanism of action of Smo inhibitors will help to broaden the usefulness of such agents. 
Development of robust criteria for the stratification of patients will also be very important for selecting 
the patients who would most likely benefit from Shh-targeted therapy. 
Despite the promising clinical results, early reports indicate that patients being treated with Smo 
inhibitors in clinical trials eventually developed resistance via number of mechanisms, involving 
mutations of the target genes, overexpression of drug transporters, or upregulation of signaling pathways 
that interact with Shh. In case of saridegib, Pgp drug transporters were overexpressed in drug resistant 
medulloblastoma tumors and resistance was partially reversed by co-treatment with Pgp inhibitor 
verapamil. Efforts to improve drug uptake with Pgp inhibitors in animal models have shown limited 
success. Yet, clinical use of Pgp inhibitors, like verapamil, was hampered by the potential for adverse 
effects at concentrations necessary to sufficiently inhibit the drug efflux proteins. Furthermore, Pgps play 
a key role in protecting noncancerous tissue from chemotherapy damage. These results suggest the need 
for additional research in two areas: the first is to continue to explore the physiological roles of ABC 
transporters, and the second is to continue to investigate novel mechanisms of drug resistance. Future 
studies examining the function of ABC transporters beyond drug efflux could not only raise awareness of 
potential adverse effects, but also identify new therapeutic targets. Given the functional redundancy 
observed for ABC transporters, combination therapy of ABC inhibitors may be explored to effectively 
inhibit given transporter function. 
Peptide-based targeted therapy studies 
Through my studies described in Chapter 4, I have computationally designed four variants of 
MKC and successfully expressed WT and one of the MKC mutants. The next steps are first, to express a 
larger library ofMKC variants using the Daedalus system. Second, to identify the top five MKC 
candidates that demonstrate highest binding affinity for glypican-2. Cell viability assays will be 
conducted to identify MKC variants that differentially affect glypican-2-dependent medulloblastoma cell 
lines. For those MKC variants that cause decreased cell viability, in vitro assays will be conducted to 
determine whether binding of the peptides results in functional inactivation of pathways that are linked to 
glypican-2 (e.g., integrin and/or protein-tyrosine phosphatase pathways). The lead candidates that emerge 
from the functional in vitro assays will be advanced to in vivo studies. Third, three MKC candidates that 
demonstrate highest efficacy in vitro will be administered systemically to Ptcc/c medulloblastoma mice to 
assess their ability to target to tumor and penetrate the blood-brain barrier at various time-points. The 
efficacy of the lead MKC variants will be tested in mice bearing patient-derived medulloblastoma 
orthotopic xenografts. These studies will assess the pharmacokinetics of the candidate peptide as well as 
its ability to engage target and inhibit tumor growth. A definitive preclinical trial will then be performed 
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in which mouse survival is the primary end-point. Although the therapeutic potentials of MKC variants 
need to be further investigated, the foundational studies performed here may provide the first insights into 
the use of cysteine knot peptide variants in mammalian systems and may serve as an important step 
towards integrating krrottin drugs into mainstream therapy. 
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